US20180185368A1 - Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders - Google Patents
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders Download PDFInfo
- Publication number
- US20180185368A1 US20180185368A1 US15/523,775 US201515523775A US2018185368A1 US 20180185368 A1 US20180185368 A1 US 20180185368A1 US 201515523775 A US201515523775 A US 201515523775A US 2018185368 A1 US2018185368 A1 US 2018185368A1
- Authority
- US
- United States
- Prior art keywords
- compound
- membered
- pyrimidine
- mmol
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FPXHUSBFYWFQNO-UHFFFAOYSA-N CCCCCOC1=CC=C(C(C)C)C=C1 Chemical compound CCCCCOC1=CC=C(C(C)C)C=C1 FPXHUSBFYWFQNO-UHFFFAOYSA-N 0.000 description 14
- JJCXHUWEIFCZJP-UHFFFAOYSA-N CC(C)C1=CC=C(C2=CC=CO2)C=N1 Chemical compound CC(C)C1=CC=C(C2=CC=CO2)C=N1 JJCXHUWEIFCZJP-UHFFFAOYSA-N 0.000 description 13
- HXIUMVXYQWTYAI-UHFFFAOYSA-N COCC#CC1=CC=C(C(C)C)C=C1 Chemical compound COCC#CC1=CC=C(C(C)C)C=C1 HXIUMVXYQWTYAI-UHFFFAOYSA-N 0.000 description 13
- YXUYRMOWOMKVIR-UHFFFAOYSA-N CC(C)C1=CC=C(C2=CC=CO2)C=C1 Chemical compound CC(C)C1=CC=C(C2=CC=CO2)C=C1 YXUYRMOWOMKVIR-UHFFFAOYSA-N 0.000 description 12
- XPQDAIPCBCVWIJ-UHFFFAOYSA-N CC(C)C1=CC=C2CCCC2=C1 Chemical compound CC(C)C1=CC=C2CCCC2=C1 XPQDAIPCBCVWIJ-UHFFFAOYSA-N 0.000 description 12
- QFRLMQZYSQYSKY-UHFFFAOYSA-N CC(C)C1CCC(C2=CC=CO2)CC1 Chemical compound CC(C)C1CCC(C2=CC=CO2)CC1 QFRLMQZYSQYSKY-UHFFFAOYSA-N 0.000 description 12
- 0 C.[1*]C1=CC([1*])=NC2=C(C(=O)NC)C=C([2*])N12 Chemical compound C.[1*]C1=CC([1*])=NC2=C(C(=O)NC)C=C([2*])N12 0.000 description 11
- WJVWBYYOECMUAO-UHFFFAOYSA-N C1=CC=C2CCCC2=C1.C1=CC=C2OCOC2=C1.CC.CC.CC(C)C.CC(C)C Chemical compound C1=CC=C2CCCC2=C1.C1=CC=C2OCOC2=C1.CC.CC.CC(C)C.CC(C)C WJVWBYYOECMUAO-UHFFFAOYSA-N 0.000 description 10
- FMLUTDAFNGHEFE-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 FMLUTDAFNGHEFE-UHFFFAOYSA-N 0.000 description 8
- ZDYJKOJYFCXGMG-UHFFFAOYSA-N C.CC.CC.CCC1=C2N=CC=CN2C=C1 Chemical compound C.CC.CC.CCC1=C2N=CC=CN2C=C1 ZDYJKOJYFCXGMG-UHFFFAOYSA-N 0.000 description 6
- CNXHPFWJORVDKO-UHFFFAOYSA-N CC(C)C(=O)C1CCC(C(C)C)N1 Chemical compound CC(C)C(=O)C1CCC(C(C)C)N1 CNXHPFWJORVDKO-UHFFFAOYSA-N 0.000 description 6
- KRVPQLTYVSYXSU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCCO4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCCO4)C3)C=CN12 KRVPQLTYVSYXSU-UHFFFAOYSA-N 0.000 description 6
- QEIUFKJMPKEAHA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN12 QEIUFKJMPKEAHA-UHFFFAOYSA-N 0.000 description 6
- PNRREAWFGADXNI-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=NN=C(C)O3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=NN=C(C)O3)C=CN12 PNRREAWFGADXNI-UHFFFAOYSA-N 0.000 description 5
- QOMQLLIDYMBBIU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC(COC4=CC=CN=C4)=C(Cl)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC(COC4=CC=CN=C4)=C(Cl)C=C3)C=CN12 QOMQLLIDYMBBIU-UHFFFAOYSA-N 0.000 description 5
- NRLPAHIQCOEYTQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN12 NRLPAHIQCOEYTQ-UHFFFAOYSA-N 0.000 description 5
- CGKWVUQDCDXEGN-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(N4CCCCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(N4CCCCC4)C=C3)C=CN12 CGKWVUQDCDXEGN-UHFFFAOYSA-N 0.000 description 5
- BVASRRNDKGKZCL-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=CC=CS4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=CC=CS4)CC3)C=CN12 BVASRRNDKGKZCL-UHFFFAOYSA-N 0.000 description 5
- UHWXLYZLHYRQAG-QAQDUYKDSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 UHWXLYZLHYRQAG-QAQDUYKDSA-N 0.000 description 5
- OQJJYRWJYKWWIJ-UHFFFAOYSA-N C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C(CO)=C1 Chemical compound C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C(CO)=C1 OQJJYRWJYKWWIJ-UHFFFAOYSA-N 0.000 description 4
- WPJMDTOLVABUNV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12 WPJMDTOLVABUNV-UHFFFAOYSA-N 0.000 description 4
- QBJXYRNWLYDMEK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4)C=CN12 QBJXYRNWLYDMEK-UHFFFAOYSA-N 0.000 description 4
- AESGGXYKBREECK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=CN=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=CN=C3)C=CN12 AESGGXYKBREECK-UHFFFAOYSA-N 0.000 description 4
- YFUQFQSLRIRHOS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)OCO4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)OCO4)C=CN12 YFUQFQSLRIRHOS-UHFFFAOYSA-N 0.000 description 4
- JTQDTEBQYFHRDU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC(C4=NC=CO4)=C(C)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC(C4=NC=CO4)=C(C)C=C3)C=CN12 JTQDTEBQYFHRDU-UHFFFAOYSA-N 0.000 description 4
- KRDOVRNGMDEKLB-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CC=CO4)C=C3)C=CN12 KRDOVRNGMDEKLB-UHFFFAOYSA-N 0.000 description 4
- AVQSNDIIBWNJBF-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CC=NC=C4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CC=NC=C4)C=C3)C=CN12 AVQSNDIIBWNJBF-UHFFFAOYSA-N 0.000 description 4
- AXUNOCIUTOTQMV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CN(C)N=C4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CN(C)N=C4)C=C3)C=CN12 AXUNOCIUTOTQMV-UHFFFAOYSA-N 0.000 description 4
- SWNNMIIVZNLATL-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CC=CS4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CC=CS4)C=C3)C=CN12 SWNNMIIVZNLATL-UHFFFAOYSA-N 0.000 description 4
- RVHMVTUZMGAGTN-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CN(C)N=C4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CN(C)N=C4)C=C3)C=CN12 RVHMVTUZMGAGTN-UHFFFAOYSA-N 0.000 description 4
- VBIZRBLDZYAZLU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=NC=C(C4=CC=CS4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=NC=C(C4=CC=CS4)C=C3)C=CN12 VBIZRBLDZYAZLU-UHFFFAOYSA-N 0.000 description 4
- ZFAKOJLZBMYYSR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=NC=CO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=NC=CO4)CC3)C=CN12 ZFAKOJLZBMYYSR-UHFFFAOYSA-N 0.000 description 4
- XWLWTNPFBCOPGZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4(CCCCO4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4(CCCCO4)C3)C=CN12 XWLWTNPFBCOPGZ-UHFFFAOYSA-N 0.000 description 4
- PBXICFAQDUIMHH-UHFFFAOYSA-N CC1=CC(OC2CCC3=C2/C=C(NC(=O)C2=C4N=C(C)C=C(C)N4C=C2)\C=C/3)=NO1 Chemical compound CC1=CC(OC2CCC3=C2/C=C(NC(=O)C2=C4N=C(C)C=C(C)N4C=C2)\C=C/3)=NO1 PBXICFAQDUIMHH-UHFFFAOYSA-N 0.000 description 4
- MIZCABWKXCWRSV-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C(F)F)=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C(F)F)=C1 MIZCABWKXCWRSV-UHFFFAOYSA-N 0.000 description 4
- AUFDTJHANLFCAR-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(C(F)F)=C1 Chemical compound CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(C(F)F)=C1 AUFDTJHANLFCAR-UHFFFAOYSA-N 0.000 description 4
- KZKOQDIQHGTNFG-UHFFFAOYSA-N CCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound CCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 KZKOQDIQHGTNFG-UHFFFAOYSA-N 0.000 description 4
- NUBXDVFRMIWTIE-UHFFFAOYSA-N CCCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 NUBXDVFRMIWTIE-UHFFFAOYSA-N 0.000 description 4
- RFENDAJCKWPVFL-IYARVYRRSA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 RFENDAJCKWPVFL-IYARVYRRSA-N 0.000 description 4
- WPVGKKNDTMPMBY-SAABIXHNSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)CC1 WPVGKKNDTMPMBY-SAABIXHNSA-N 0.000 description 4
- WPLBTFBQEHOQDX-UHFFFAOYSA-N COCC#CC1=NC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound COCC#CC1=NC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 WPLBTFBQEHOQDX-UHFFFAOYSA-N 0.000 description 4
- UFJXLUMXKZLELX-UHFFFAOYSA-N C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)=CC=C1 Chemical compound C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)=CC=C1 UFJXLUMXKZLELX-UHFFFAOYSA-N 0.000 description 3
- NBNPTHRUBZZIAD-UHFFFAOYSA-N C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)=CC=C1 Chemical compound C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)=CC=C1 NBNPTHRUBZZIAD-UHFFFAOYSA-N 0.000 description 3
- XKRZGNUKQYJFIO-UHFFFAOYSA-N C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)C=C1 Chemical compound C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)C=C1 XKRZGNUKQYJFIO-UHFFFAOYSA-N 0.000 description 3
- SWIXYYIDYMERBU-UHFFFAOYSA-N C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)C=C1 Chemical compound C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)C=C1 SWIXYYIDYMERBU-UHFFFAOYSA-N 0.000 description 3
- OUQKAKCFJMZRLM-IYARVYRRSA-N C#CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound C#CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 OUQKAKCFJMZRLM-IYARVYRRSA-N 0.000 description 3
- NCBQNWCYHDQWPD-UHFFFAOYSA-N CC1=CC(Br)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 Chemical compound CC1=CC(Br)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 NCBQNWCYHDQWPD-UHFFFAOYSA-N 0.000 description 3
- HGLRHKHKOXRRFB-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=CC=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=CC=CC=C3)C=CN12 HGLRHKHKOXRRFB-UHFFFAOYSA-N 0.000 description 3
- DIIQEQZCMXTFQY-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C(C)C=C(C4=NC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C(C)C=C(C4=NC=CO4)C=C3)C=CN12 DIIQEQZCMXTFQY-UHFFFAOYSA-N 0.000 description 3
- LWRGLCLHHOEBEG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C(Cl)C=C(C4=NC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C(Cl)C=C(C4=NC=CO4)C=C3)C=CN12 LWRGLCLHHOEBEG-UHFFFAOYSA-N 0.000 description 3
- JAOFCZSUFKEVSU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4O)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4O)C=CN12 JAOFCZSUFKEVSU-UHFFFAOYSA-N 0.000 description 3
- SJEFZPMTVJQPFR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=CC=N3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=CC=N3)C=CN12 SJEFZPMTVJQPFR-UHFFFAOYSA-N 0.000 description 3
- TVLGULJMMQGEPO-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C4CCCC4=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C4CCCC4=CC=C3)C=CN12 TVLGULJMMQGEPO-UHFFFAOYSA-N 0.000 description 3
- JVGHBKFRCHMBKC-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN12 JVGHBKFRCHMBKC-UHFFFAOYSA-N 0.000 description 3
- ZHSFGRVOZYDXQP-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C(=O)N(C)C4CC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C(=O)N(C)C4CC4)CC3)C=CN12 ZHSFGRVOZYDXQP-UHFFFAOYSA-N 0.000 description 3
- HGSLWEZJZKRASW-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4CCCO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4CCCO4)CC3)C=CN12 HGSLWEZJZKRASW-UHFFFAOYSA-N 0.000 description 3
- NSDZZHCPSDTENW-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCCO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCCO4)CC3)C=CN12 NSDZZHCPSDTENW-UHFFFAOYSA-N 0.000 description 3
- DIFKLLFHMUMXEY-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C3)C=CN12 DIFKLLFHMUMXEY-UHFFFAOYSA-N 0.000 description 3
- VHTSKDVSCDBUAB-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)CC3)C=CN12 VHTSKDVSCDBUAB-UHFFFAOYSA-N 0.000 description 3
- PKXOAIPHCSRCBS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC(OC4=CC=CS4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC(OC4=CC=CS4)C3)C=CN12 PKXOAIPHCSRCBS-UHFFFAOYSA-N 0.000 description 3
- VELCARYWDCLCCN-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC34CCCCO4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC34CCCCO4)C=CN12 VELCARYWDCLCCN-UHFFFAOYSA-N 0.000 description 3
- ZQNOYXXECNASJS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(C#N)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(C#N)C=C4)C=CN12 ZQNOYXXECNASJS-UHFFFAOYSA-N 0.000 description 3
- MLJQXEGYFHBZCJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCCC34CCCCO4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCCC34CCCCO4)C=CN12 MLJQXEGYFHBZCJ-UHFFFAOYSA-N 0.000 description 3
- AXOALQFVWTWTPG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCCC4=C3C=CC=C4)C=CN12 AXOALQFVWTWTPG-UHFFFAOYSA-N 0.000 description 3
- DBKZMMLKFHVFJR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=CC=C4)C=CN12 DBKZMMLKFHVFJR-UHFFFAOYSA-N 0.000 description 3
- KVAOBSITTDZWQZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=CC=C4F)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=CC=C4F)C=CN12 KVAOBSITTDZWQZ-UHFFFAOYSA-N 0.000 description 3
- RPRCQAOOXYOLMD-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC=C4)C=CN12 RPRCQAOOXYOLMD-UHFFFAOYSA-N 0.000 description 3
- PTNNMPDGCFZVCK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NCC3CCC4(CCCCO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NCC3CCC4(CCCCO4)CC3)C=CN12 PTNNMPDGCFZVCK-UHFFFAOYSA-N 0.000 description 3
- BDTJIBOTOSNXST-WKILWMFISA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC(C)C)CC3)C=CN12 BDTJIBOTOSNXST-WKILWMFISA-N 0.000 description 3
- ILIFNGGJKMAQNS-QAQDUYKDSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN12 ILIFNGGJKMAQNS-QAQDUYKDSA-N 0.000 description 3
- LIMQTVIVKIKLSM-QAQDUYKDSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC4CC(F)(F)C4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC4CC(F)(F)C4)CC3)C=CN12 LIMQTVIVKIKLSM-QAQDUYKDSA-N 0.000 description 3
- MJRVZKSQDCIQRW-UHFFFAOYSA-N CC1=CC(OC2CCC(NC(=O)C3=C4N=C(C)C=C(C)N4C=C3)C2)=NO1 Chemical compound CC1=CC(OC2CCC(NC(=O)C3=C4N=C(C)C=C(C)N4C=C3)C2)=NO1 MJRVZKSQDCIQRW-UHFFFAOYSA-N 0.000 description 3
- YAFRHGBHSYVRSW-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC(C)(C)C3=CC=CC=C3)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC(C)(C)C3=CC=CC=C3)C=CN12 YAFRHGBHSYVRSW-UHFFFAOYSA-N 0.000 description 3
- CLQJFXDTJBPUFB-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C=C4)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C=C4)C=CN12 CLQJFXDTJBPUFB-UHFFFAOYSA-N 0.000 description 3
- RJRSWNYOHUKSSO-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(O)=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(O)=C1 RJRSWNYOHUKSSO-UHFFFAOYSA-N 0.000 description 3
- OWSCUJUBVZKSQV-WGSAOQKQSA-N CCCCCN(C)C(=O)[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCCCN(C)C(=O)[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 OWSCUJUBVZKSQV-WGSAOQKQSA-N 0.000 description 3
- QAEYTVNYOPLOEQ-UHFFFAOYSA-N CCCCCOC1CCCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCOC1CCCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 QAEYTVNYOPLOEQ-UHFFFAOYSA-N 0.000 description 3
- NUBXDVFRMIWTIE-DLBZAZTESA-N CCCCCO[C@@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCO[C@@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 NUBXDVFRMIWTIE-DLBZAZTESA-N 0.000 description 3
- RFENDAJCKWPVFL-HDICACEKSA-N CCCCCO[C@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 RFENDAJCKWPVFL-HDICACEKSA-N 0.000 description 3
- UIYCKGDDDATABX-IYARVYRRSA-N CCCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 UIYCKGDDDATABX-IYARVYRRSA-N 0.000 description 3
- OMYPJGXCPHBEBR-WKILWMFISA-N CCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 OMYPJGXCPHBEBR-WKILWMFISA-N 0.000 description 3
- LSTHUTUVMPUQIN-HDJSIYSDSA-N CCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 Chemical compound CCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 LSTHUTUVMPUQIN-HDJSIYSDSA-N 0.000 description 3
- BWQNZMXEMABOOL-UHFFFAOYSA-N CCOC1(C)CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCOC1(C)CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 BWQNZMXEMABOOL-UHFFFAOYSA-N 0.000 description 3
- XVOMDDGTOJWYGX-QGZVFWFLSA-N CC[C@@H](NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 Chemical compound CC[C@@H](NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 XVOMDDGTOJWYGX-QGZVFWFLSA-N 0.000 description 3
- DCUAJQWEPDBKHO-UHFFFAOYSA-N COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=CC(C2=COC=N2)=C1 Chemical compound COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=CC(C2=COC=N2)=C1 DCUAJQWEPDBKHO-UHFFFAOYSA-N 0.000 description 3
- CYXACTYCJLGPQE-UHFFFAOYSA-N COC1CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 Chemical compound COC1CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 CYXACTYCJLGPQE-UHFFFAOYSA-N 0.000 description 3
- QDLMTSRPINAZHL-UHFFFAOYSA-N COCC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C)=C1 Chemical compound COCC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C)=C1 QDLMTSRPINAZHL-UHFFFAOYSA-N 0.000 description 3
- QEXVLKXWTMOSCA-UHFFFAOYSA-N COCCOC1=CC2=C(C=C1)CCCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound COCCOC1=CC2=C(C=C1)CCCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 QEXVLKXWTMOSCA-UHFFFAOYSA-N 0.000 description 3
- WVKFAVWLRQJIMG-IYARVYRRSA-N COCCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound COCCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 WVKFAVWLRQJIMG-IYARVYRRSA-N 0.000 description 3
- WVNDCVZQVPOPTQ-UHFFFAOYSA-N C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)=CC=C1 Chemical compound C#CC1=CC(C(C)(C)NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)=CC=C1 WVNDCVZQVPOPTQ-UHFFFAOYSA-N 0.000 description 2
- LWCVOHPSRCZKID-UHFFFAOYSA-N C#CC1=CC(OC)=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound C#CC1=CC(OC)=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 LWCVOHPSRCZKID-UHFFFAOYSA-N 0.000 description 2
- HNNWRBODSZUJOH-UHFFFAOYSA-N C#CC1=CC(OCCOC)=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound C#CC1=CC(OCCOC)=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 HNNWRBODSZUJOH-UHFFFAOYSA-N 0.000 description 2
- KPUIZYSVQAOTFP-UHFFFAOYSA-N C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)C=C1 Chemical compound C#CC1=CC=C(C(C)(C)NC(=O)C2=C3N=C(C)C=C(COC)N3C=C2)C=C1 KPUIZYSVQAOTFP-UHFFFAOYSA-N 0.000 description 2
- BRSLZCUCLMPPQC-UHFFFAOYSA-N C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 BRSLZCUCLMPPQC-UHFFFAOYSA-N 0.000 description 2
- JMWIAXUSAOBPOA-UHFFFAOYSA-N C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=N1 Chemical compound C#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=N1 JMWIAXUSAOBPOA-UHFFFAOYSA-N 0.000 description 2
- TXVRCTVWYXTSPM-WGSAOQKQSA-N C#CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound C#CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 TXVRCTVWYXTSPM-WGSAOQKQSA-N 0.000 description 2
- BPGYFHVXIXJMJC-UHFFFAOYSA-N C#CCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound C#CCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 BPGYFHVXIXJMJC-UHFFFAOYSA-N 0.000 description 2
- LQVDZKQXJHGIKP-UHFFFAOYSA-N C.CNC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound C.CNC(=O)C1=C2N=C(C)C=C(C)N2C=C1 LQVDZKQXJHGIKP-UHFFFAOYSA-N 0.000 description 2
- QHSBTCYWMBYWMY-SFHVURJKSA-N CC(C)C1=CC=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC(C)C1=CC=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 QHSBTCYWMBYWMY-SFHVURJKSA-N 0.000 description 2
- RVVJYZRBKLWRKA-UHFFFAOYSA-N CC1=CC(=O)N(C2CCC3=C2/C=C(NC(=O)C2=C4N=C(C)C=C(C)N4C=C2)\C=C/3)O1 Chemical compound CC1=CC(=O)N(C2CCC3=C2/C=C(NC(=O)C2=C4N=C(C)C=C(C)N4C=C2)\C=C/3)O1 RVVJYZRBKLWRKA-UHFFFAOYSA-N 0.000 description 2
- WVDJEGQQSUURMN-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=C(Cl)C=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=C(Cl)C=CC=C3)C=CN12 WVDJEGQQSUURMN-UHFFFAOYSA-N 0.000 description 2
- HGIFGZRRQHZVGJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C(F)=C(F)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C(F)=C(F)C=C4)C=CN12 HGIFGZRRQHZVGJ-UHFFFAOYSA-N 0.000 description 2
- HTRZWZREKGXAEQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C(F)=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C(F)=CC=C4)C=CN12 HTRZWZREKGXAEQ-UHFFFAOYSA-N 0.000 description 2
- OMWWPZROPGXKLL-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 OMWWPZROPGXKLL-UHFFFAOYSA-N 0.000 description 2
- WLDGUODEFDCGNE-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4)C=CN12 WLDGUODEFDCGNE-UHFFFAOYSA-N 0.000 description 2
- AIPPLIAAXVCUAG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4F)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4F)C=CN12 AIPPLIAAXVCUAG-UHFFFAOYSA-N 0.000 description 2
- HQQHQJYFJNYCLA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC34CCC(CC3)C3=C4C=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC34CCC(CC3)C3=C4C=CC=C3)C=CN12 HQQHQJYFJNYCLA-UHFFFAOYSA-N 0.000 description 2
- VBTXULBWLDBSPA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)S4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC4=C(C=C3)N=C(C)S4)C=CN12 VBTXULBWLDBSPA-UHFFFAOYSA-N 0.000 description 2
- CWLZNUBVFHWGLJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=C(F)N12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=C(F)N12 CWLZNUBVFHWGLJ-UHFFFAOYSA-N 0.000 description 2
- YBJPKSSRHPUYCZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)N=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)N=C3)C=CN12 YBJPKSSRHPUYCZ-UHFFFAOYSA-N 0.000 description 2
- FNGSZJBEQMCHQE-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(Cl)C(C4=CN=CO4)=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(Cl)C(C4=CN=CO4)=C3)C=CN12 FNGSZJBEQMCHQE-UHFFFAOYSA-N 0.000 description 2
- GHLRRRATTHVRHS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(N4C=CN=C4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(N4C=CN=C4)C=C3)C=CN12 GHLRRRATTHVRHS-UHFFFAOYSA-N 0.000 description 2
- WYKUNUSJRVKDLV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCCCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCCCC4)C=C3)C=CN12 WYKUNUSJRVKDLV-UHFFFAOYSA-N 0.000 description 2
- WAKOHRSGIAXIFR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=NC=CC=N4)C(Cl)=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=NC=CC=N4)C(Cl)=C3)C=CN12 WAKOHRSGIAXIFR-UHFFFAOYSA-N 0.000 description 2
- CCDVZOCQANZEPS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=NC=C(C4=CC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=NC=C(C4=CC=CO4)C=C3)C=CN12 CCDVZOCQANZEPS-UHFFFAOYSA-N 0.000 description 2
- XRJDICDYILQZTQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=C(C5=CSC=N5)C=C4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=C(C5=CSC=N5)C=C4)C3)C=CN12 XRJDICDYILQZTQ-UHFFFAOYSA-N 0.000 description 2
- FCNJKNMDXXJLMZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=C(C5=NC=CO5)C=C4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=C(C5=NC=CO5)C=C4)C3)C=CN12 FCNJKNMDXXJLMZ-UHFFFAOYSA-N 0.000 description 2
- GPUBWRIGMODONO-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=CC=C4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC4=C(C=CC=C4)C3)C=CN12 GPUBWRIGMODONO-UHFFFAOYSA-N 0.000 description 2
- BRAGHRAYBRZGSG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC4CCC(C3)N4CC(F)(F)F)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC4CCC(C3)N4CC(F)(F)F)C=CN12 BRAGHRAYBRZGSG-UHFFFAOYSA-N 0.000 description 2
- NZQGMLJRXMNPDZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC4CCC(C3)O4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC4CCC(C3)O4)C=CN12 NZQGMLJRXMNPDZ-UHFFFAOYSA-N 0.000 description 2
- CZQHMFKRJFYSCK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC=C(C4=CC=CS4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC=C(C4=CC=CS4)CC3)C=CN12 CZQHMFKRJFYSCK-UHFFFAOYSA-N 0.000 description 2
- WIZOCFKUSXWIPZ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC=C(C4=NC=CO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC=C(C4=NC=CO4)CC3)C=CN12 WIZOCFKUSXWIPZ-UHFFFAOYSA-N 0.000 description 2
- NXXUBXRWSVURLB-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(F)(F)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(F)(F)CC3)C=CN12 NXXUBXRWSVURLB-UHFFFAOYSA-N 0.000 description 2
- RUUBIJWBAGDTQJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CN=C4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CN=C4)C3)C=CN12 RUUBIJWBAGDTQJ-UHFFFAOYSA-N 0.000 description 2
- BZBAIVGEHXZMGP-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCOCC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCOCC4)CC3)C=CN12 BZBAIVGEHXZMGP-UHFFFAOYSA-N 0.000 description 2
- ZXPXFDNUEHHLPF-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C3)OC(C)=N4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C3)OC(C)=N4)C=CN12 ZXPXFDNUEHHLPF-UHFFFAOYSA-N 0.000 description 2
- FWNMGVYYXYXEDY-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C3)SC(C)=N4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C3)SC(C)=N4)C=CN12 FWNMGVYYXYXEDY-UHFFFAOYSA-N 0.000 description 2
- SMAUNCYCROJIQK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C=CC=C4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C(C=CC=C4)C3)C=CN12 SMAUNCYCROJIQK-UHFFFAOYSA-N 0.000 description 2
- BFNGCLVIFDIKAG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C3C=C(C3=COC=N3)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C3C=C(C3=COC=N3)C=C4)C=CN12 BFNGCLVIFDIKAG-UHFFFAOYSA-N 0.000 description 2
- YUYLKLSMZVDHIT-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4OCOC4C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4OCOC4C3)C=CN12 YUYLKLSMZVDHIT-UHFFFAOYSA-N 0.000 description 2
- ZHHDDPXURXBFBN-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(C3=COC=N3)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(C3=COC=N3)C=C4)C=CN12 ZHHDDPXURXBFBN-UHFFFAOYSA-N 0.000 description 2
- ZGBWKPAQPTURFQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(S(C)(=O)=O)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=C(S(C)(=O)=O)C=C4)C=CN12 ZGBWKPAQPTURFQ-UHFFFAOYSA-N 0.000 description 2
- VBUZZLMBWAMKAF-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=CN=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=CN=C4)C=CN12 VBUZZLMBWAMKAF-UHFFFAOYSA-N 0.000 description 2
- KCCYGWMCPGSJOL-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=NC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3C=NC=C4)C=CN12 KCCYGWMCPGSJOL-UHFFFAOYSA-N 0.000 description 2
- PFFWQPKNPJHLPA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3N=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCC4=C3N=CC=C4)C=CN12 PFFWQPKNPJHLPA-UHFFFAOYSA-N 0.000 description 2
- AOUZDNDMVUYPQX-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCCCC34CCOCC4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCCCC34CCOCC4)C=CN12 AOUZDNDMVUYPQX-UHFFFAOYSA-N 0.000 description 2
- CHKWJZOJHAUEPM-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCN(C4=CSC=C4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCN(C4=CSC=C4)CC3)C=CN12 CHKWJZOJHAUEPM-UHFFFAOYSA-N 0.000 description 2
- CECRXPMJYFIFRQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCN(CC(F)(F)F)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCN(CC(F)(F)F)C3)C=CN12 CECRXPMJYFIFRQ-UHFFFAOYSA-N 0.000 description 2
- FHSBFLPTNONWTR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=C(F)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C(F)=C(F)C=C4)C=CN12 FHSBFLPTNONWTR-UHFFFAOYSA-N 0.000 description 2
- VCWGXHDCFKXQBD-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=C(C3=NC=CO3)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=C(C3=NC=CO3)C=C4)C=CN12 VCWGXHDCFKXQBD-UHFFFAOYSA-N 0.000 description 2
- RBANBGBPEHWVIO-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=C(F)C=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=C(F)C=C4)C=CN12 RBANBGBPEHWVIO-UHFFFAOYSA-N 0.000 description 2
- BUTCJIZPBARLCJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC(F)=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC(F)=C4)C=CN12 BUTCJIZPBARLCJ-UHFFFAOYSA-N 0.000 description 2
- KWUIGIUKPXGQPW-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC=C4F)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCOC4=C3C=CC=C4F)C=CN12 KWUIGIUKPXGQPW-UHFFFAOYSA-N 0.000 description 2
- UOQLDNYRYHPPDM-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3COCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3COCC4=C3C=CC=C4)C=CN12 UOQLDNYRYHPPDM-UHFFFAOYSA-N 0.000 description 2
- XKMXPDVLSOYDDG-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NCC3CCC(F)(F)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NCC3CCC(F)(F)CC3)C=CN12 XKMXPDVLSOYDDG-UHFFFAOYSA-N 0.000 description 2
- FFQPAKAKJOTSTI-ZDUSSCGKSA-N CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=C(F)C=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=C(F)C=CC=C3)C=CN12 FFQPAKAKJOTSTI-ZDUSSCGKSA-N 0.000 description 2
- LIFPVHNGRQGCHH-ZDUSSCGKSA-N CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=CC=C(F)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=CC=C(F)C=C3)C=CN12 LIFPVHNGRQGCHH-ZDUSSCGKSA-N 0.000 description 2
- XEHQPZWJRYRESF-AWEZNQCLSA-N CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=CC=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@@H](C)C3=CC=CC=C3)C=CN12 XEHQPZWJRYRESF-AWEZNQCLSA-N 0.000 description 2
- QDODMGUAZNSCSC-QGZVFWFLSA-N CC1=CC(C)=NC2=C(C(=O)N[C@@H]3CCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@@H]3CCC4=C3C=CC=C4)C=CN12 QDODMGUAZNSCSC-QGZVFWFLSA-N 0.000 description 2
- QEIUFKJMPKEAHA-GOSISDBHSA-N CC1=CC(C)=NC2=C(C(=O)N[C@@H]3CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@@H]3CCCC4=C3C=CC=C4)C=CN12 QEIUFKJMPKEAHA-GOSISDBHSA-N 0.000 description 2
- XEHQPZWJRYRESF-CQSZACIVSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H](C)C3=CC=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H](C)C3=CC=CC=C3)C=CN12 XEHQPZWJRYRESF-CQSZACIVSA-N 0.000 description 2
- QDODMGUAZNSCSC-KRWDZBQOSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CCC4=C3C=CC=C4)C=CN12 QDODMGUAZNSCSC-KRWDZBQOSA-N 0.000 description 2
- QEIUFKJMPKEAHA-SFHVURJKSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 QEIUFKJMPKEAHA-SFHVURJKSA-N 0.000 description 2
- XXZAUBHUTFSBLL-IYBDPMFKSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OC4=CC=CS4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OC4=CC=CS4)CC3)C=CN12 XXZAUBHUTFSBLL-IYBDPMFKSA-N 0.000 description 2
- ZQAUSLMGMAPKOK-WKILWMFISA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC(C)(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC(C)(C)C)CC3)C=CN12 ZQAUSLMGMAPKOK-WKILWMFISA-N 0.000 description 2
- XXZAUBHUTFSBLL-WKILWMFISA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=CC=CS4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=CC=CS4)CC3)C=CN12 XXZAUBHUTFSBLL-WKILWMFISA-N 0.000 description 2
- JXEDUURJGCBPII-QAQDUYKDSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=CN=CC=C4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=CN=CC=C4)CC3)C=CN12 JXEDUURJGCBPII-QAQDUYKDSA-N 0.000 description 2
- SHHQRFFBCFCXOB-WKILWMFISA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=NC=CC=N4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4=NC=CC=N4)CC3)C=CN12 SHHQRFFBCFCXOB-WKILWMFISA-N 0.000 description 2
- AHDLHSKWJBBWLS-SHTZXODSSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CC4)CC3)C=CN12 AHDLHSKWJBBWLS-SHTZXODSSA-N 0.000 description 2
- ZETCNFVCAIBUEO-SAABIXHNSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CCCC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CCCC4)CC3)C=CN12 ZETCNFVCAIBUEO-SAABIXHNSA-N 0.000 description 2
- RWULBLVECYQEMM-UHFFFAOYSA-N CC1=CC(Cl)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 Chemical compound CC1=CC(Cl)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 RWULBLVECYQEMM-UHFFFAOYSA-N 0.000 description 2
- ACVFHCHNYHFUGP-UHFFFAOYSA-N CC1=CC(Cl)=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN12 Chemical compound CC1=CC(Cl)=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN12 ACVFHCHNYHFUGP-UHFFFAOYSA-N 0.000 description 2
- RSWGKOXMDJBFQS-SHTZXODSSA-N CC1=CC(Cl)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN12 Chemical compound CC1=CC(Cl)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN12 RSWGKOXMDJBFQS-SHTZXODSSA-N 0.000 description 2
- NRMNXPXFWHSRHS-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC3(C)CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC3(C)CCCC4=C3C=CC=C4)C=CN12 NRMNXPXFWHSRHS-UHFFFAOYSA-N 0.000 description 2
- AWCBKCBPMGXAMZ-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4)C=CN12 AWCBKCBPMGXAMZ-UHFFFAOYSA-N 0.000 description 2
- LEGSXLNPYCDIQR-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4F)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC3(C)CCOC4=C3C=CC=C4F)C=CN12 LEGSXLNPYCDIQR-UHFFFAOYSA-N 0.000 description 2
- MCQLHLMYMCJMDZ-UHFFFAOYSA-N CC1=CC=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN12 MCQLHLMYMCJMDZ-UHFFFAOYSA-N 0.000 description 2
- FVAPRFCAZDKQFO-GFCCVEGCSA-N CC1=CC=NC2=C(C(=O)N[C@H](C)C3=CC=C(F)C=C3)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)N[C@H](C)C3=CC=C(F)C=C3)C=CN12 FVAPRFCAZDKQFO-GFCCVEGCSA-N 0.000 description 2
- YWQQXVFHQYJBDF-KRWDZBQOSA-N CC1=CC=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN12 YWQQXVFHQYJBDF-KRWDZBQOSA-N 0.000 description 2
- XPXHYNNHFSCZEF-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(Br)=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(Br)=C1 XPXHYNNHFSCZEF-UHFFFAOYSA-N 0.000 description 2
- MJWVZCBPPXRBRD-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C(F)(F)F)=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(C(F)(F)F)=C1 MJWVZCBPPXRBRD-UHFFFAOYSA-N 0.000 description 2
- DDXZNKLGOUYWPR-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(Cl)=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN2C(Cl)=C1 DDXZNKLGOUYWPR-UHFFFAOYSA-N 0.000 description 2
- JBTQKGCUZQSIBI-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN2C=C1 Chemical compound CC1=NC2=C(C(=O)NC3=CC=C(C4=NC=CO4)C=C3)C=CN2C=C1 JBTQKGCUZQSIBI-UHFFFAOYSA-N 0.000 description 2
- JAFDOUIUROSPMC-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(C(F)(F)F)=C1 Chemical compound CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(C(F)(F)F)=C1 JAFDOUIUROSPMC-UHFFFAOYSA-N 0.000 description 2
- MWVXIQBHGZVFEG-UHFFFAOYSA-N CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(O)=C1 Chemical compound CC1=NC2=C(C(=O)NC3CCCC4=C3C=CC=C4)C=CN2C(O)=C1 MWVXIQBHGZVFEG-UHFFFAOYSA-N 0.000 description 2
- CLBCYUGGKOENKY-QAQDUYKDSA-N CC1=NC2=C(C(=O)N[C@H]3CC[C@H](OCCCC(F)(F)F)CC3)C=CN2C(C2CC2)=C1 Chemical compound CC1=NC2=C(C(=O)N[C@H]3CC[C@H](OCCCC(F)(F)F)CC3)C=CN2C(C2CC2)=C1 CLBCYUGGKOENKY-QAQDUYKDSA-N 0.000 description 2
- QHIRSGMSBDDIOB-UHFFFAOYSA-N CCC(C)(NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 Chemical compound CCC(C)(NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 QHIRSGMSBDDIOB-UHFFFAOYSA-N 0.000 description 2
- DXOLVAODWHUMHW-UHFFFAOYSA-N CCC(F)(F)CN1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCC(F)(F)CN1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 DXOLVAODWHUMHW-UHFFFAOYSA-N 0.000 description 2
- QTAWDKCVMKVIPG-UHFFFAOYSA-N CCC(F)(F)CN1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCC(F)(F)CN1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 QTAWDKCVMKVIPG-UHFFFAOYSA-N 0.000 description 2
- AEJLGWWTMSPHGH-UHFFFAOYSA-N CCCCCC(=O)N1C2CCC1CC(NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C2 Chemical compound CCCCCC(=O)N1C2CCC1CC(NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C2 AEJLGWWTMSPHGH-UHFFFAOYSA-N 0.000 description 2
- NUBXDVFRMIWTIE-IAGOWNOFSA-N CCCCCO[C@@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCO[C@@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 NUBXDVFRMIWTIE-IAGOWNOFSA-N 0.000 description 2
- NUBXDVFRMIWTIE-SJORKVTESA-N CCCCCO[C@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCO[C@H]1CC[C@@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 NUBXDVFRMIWTIE-SJORKVTESA-N 0.000 description 2
- SFUGTYVUZLJDFX-WKILWMFISA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C(F)F)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C(F)F)N3C=C2)CC1 SFUGTYVUZLJDFX-WKILWMFISA-N 0.000 description 2
- NUBXDVFRMIWTIE-IRXDYDNUSA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 NUBXDVFRMIWTIE-IRXDYDNUSA-N 0.000 description 2
- DTZDNUNOUKNGGY-WGSAOQKQSA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C4CC4)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C4CC4)N3C=C2)CC1 DTZDNUNOUKNGGY-WGSAOQKQSA-N 0.000 description 2
- OPMBODPYEKTTGD-IRJFHVNHSA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(COC)N3C=C2)CC1 OPMBODPYEKTTGD-IRJFHVNHSA-N 0.000 description 2
- BWCKEBZHYLGZTN-QAQDUYKDSA-N CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=CC=C(C)N3C=C2)CC1 Chemical compound CCCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=CC=C(C)N3C=C2)CC1 BWCKEBZHYLGZTN-QAQDUYKDSA-N 0.000 description 2
- WSVZQGZKWNWHIK-UHFFFAOYSA-N CCCCOC(=O)N1CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCOC(=O)N1CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 WSVZQGZKWNWHIK-UHFFFAOYSA-N 0.000 description 2
- VGJGQKOIDSGKID-VCWGHTDQSA-N CCCCO[C@H]1CC2CCC(C1)[C@H]2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound CCCCO[C@H]1CC2CCC(C1)[C@H]2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 VGJGQKOIDSGKID-VCWGHTDQSA-N 0.000 description 2
- AWVUPPVDKKNMAD-SHTZXODSSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C(F)F)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C(F)F)N3C=C2)CC1 AWVUPPVDKKNMAD-SHTZXODSSA-N 0.000 description 2
- WCSJOFCZJZOGIR-IYARVYRRSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C4CC4)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C4CC4)N3C=C2)CC1 WCSJOFCZJZOGIR-IYARVYRRSA-N 0.000 description 2
- VDHUQHCZBUYYLA-KOMQPUFPSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(F)F)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(F)F)N3C=C2)CC1 VDHUQHCZBUYYLA-KOMQPUFPSA-N 0.000 description 2
- XHZWYWCLPAJUIW-SAABIXHNSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C)N3C=C2)CC1 XHZWYWCLPAJUIW-SAABIXHNSA-N 0.000 description 2
- VSGWZAZADIEJIX-SHTZXODSSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(F)C=C(C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(F)C=C(C)N3C=C2)CC1 VSGWZAZADIEJIX-SHTZXODSSA-N 0.000 description 2
- DXNWVGILOXMTMO-SHTZXODSSA-N CCCCO[C@H]1C[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCCO[C@H]1C[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 DXNWVGILOXMTMO-SHTZXODSSA-N 0.000 description 2
- RKIPPMCAQCRQFV-DSWCUTRASA-N CCCCO[C@H]1[C@H]2CC[C@@H]1C[C@@H](NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C2 Chemical compound CCCCO[C@H]1[C@H]2CC[C@@H]1C[C@@H](NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C2 RKIPPMCAQCRQFV-DSWCUTRASA-N 0.000 description 2
- VSPMNRYYMISULB-QAQDUYKDSA-N CCCOC[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCOC[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 VSPMNRYYMISULB-QAQDUYKDSA-N 0.000 description 2
- NXKVAFFWCMHSQP-QAQDUYKDSA-N CCCO[C@H]1CC[C@H](CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCO[C@H]1CC[C@H](CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 NXKVAFFWCMHSQP-QAQDUYKDSA-N 0.000 description 2
- XKJUSNOUOLSNJN-UHFFFAOYSA-N CCOC(=O)C1=C(N)NC=C1 Chemical compound CCOC(=O)C1=C(N)NC=C1 XKJUSNOUOLSNJN-UHFFFAOYSA-N 0.000 description 2
- YYLRQRUBJFCFOO-UHFFFAOYSA-N CCOCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 Chemical compound CCOCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 YYLRQRUBJFCFOO-UHFFFAOYSA-N 0.000 description 2
- CUWIDFBNFMKOIA-QAQDUYKDSA-N CCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCOCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 CUWIDFBNFMKOIA-QAQDUYKDSA-N 0.000 description 2
- UEIXVPMJWAVYEL-SHTZXODSSA-N CCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 UEIXVPMJWAVYEL-SHTZXODSSA-N 0.000 description 2
- ZYOPIGREXWMRSV-BRWVUGGUSA-N CC[C@@H](C)O[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CC[C@@H](C)O[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 ZYOPIGREXWMRSV-BRWVUGGUSA-N 0.000 description 2
- ZYOPIGREXWMRSV-ULQDDVLXSA-N CC[C@H](C)O[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CC[C@H](C)O[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 ZYOPIGREXWMRSV-ULQDDVLXSA-N 0.000 description 2
- XVOMDDGTOJWYGX-KRWDZBQOSA-N CC[C@H](NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 Chemical compound CC[C@H](NC(=O)C1=C2N=C(C)C=C(C)N2C=C1)C1=CC=CC=C1 XVOMDDGTOJWYGX-KRWDZBQOSA-N 0.000 description 2
- ANUUMOCZJRDCNK-UHFFFAOYSA-N COC1=C(C2=CN=CO2)C=CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)=C1 Chemical compound COC1=C(C2=CN=CO2)C=CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)=C1 ANUUMOCZJRDCNK-UHFFFAOYSA-N 0.000 description 2
- OMBQIBSMUVEHRQ-UHFFFAOYSA-N COC1=C(C2=COC=N2)C=CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)=C1 Chemical compound COC1=C(C2=COC=N2)C=CC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)=C1 OMBQIBSMUVEHRQ-UHFFFAOYSA-N 0.000 description 2
- MOSJCCVWPJEEHQ-UHFFFAOYSA-N COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=CC(C2=CN=CO2)=C1 Chemical compound COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=CC(C2=CN=CO2)=C1 MOSJCCVWPJEEHQ-UHFFFAOYSA-N 0.000 description 2
- AWODPTOOAKLKTM-UHFFFAOYSA-N COC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 Chemical compound COC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=COC=N4)C=C3)C=CN12 AWODPTOOAKLKTM-UHFFFAOYSA-N 0.000 description 2
- JYTYRVKLSLSYTG-UHFFFAOYSA-N COC1=CC=CC=C1C(C)(C)NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound COC1=CC=CC=C1C(C)(C)NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 JYTYRVKLSLSYTG-UHFFFAOYSA-N 0.000 description 2
- KMLCDPOAYQPXNQ-UHFFFAOYSA-N COC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 Chemical compound COC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C2=C1C=CC=C2 KMLCDPOAYQPXNQ-UHFFFAOYSA-N 0.000 description 2
- ILCOFMFYWSMLKF-UHFFFAOYSA-N COC1CCC2=C1C=C(NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C=C2 Chemical compound COC1CCC2=C1C=C(NC(=O)C1=C3N=C(C)C=C(C)N3C=C1)C=C2 ILCOFMFYWSMLKF-UHFFFAOYSA-N 0.000 description 2
- JCSUPWUHSCGXIB-UHFFFAOYSA-N COC1CCCCC1NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound COC1CCCCC1NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 JCSUPWUHSCGXIB-UHFFFAOYSA-N 0.000 description 2
- GJJATHCRTHBAMN-UHFFFAOYSA-N COCC#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound COCC#CC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 GJJATHCRTHBAMN-UHFFFAOYSA-N 0.000 description 2
- BOXSJSGFXJDVRP-UHFFFAOYSA-N COCC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=CC=C(C4=COC=N4)C=C3)C=CN12 Chemical compound COCC1=CC(C)=NC2=C(C(=O)NC(C)(C)C3=CC=C(C4=COC=N4)C=C3)C=CN12 BOXSJSGFXJDVRP-UHFFFAOYSA-N 0.000 description 2
- ZWXBVLNVBYKLIQ-UHFFFAOYSA-N COCC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 Chemical compound COCC1=CC(C)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 ZWXBVLNVBYKLIQ-UHFFFAOYSA-N 0.000 description 2
- JPNKLUHYIYMFHY-UHFFFAOYSA-N COCC1=CC(COC)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 Chemical compound COCC1=CC(COC)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 JPNKLUHYIYMFHY-UHFFFAOYSA-N 0.000 description 2
- BGFXQLIFXSVVLS-UHFFFAOYSA-N COCC1=NC2=C(C(=O)NC(C)(C)C3=CC=C(C4=COC=N4)C=C3)C=CN2C(C)=C1 Chemical compound COCC1=NC2=C(C(=O)NC(C)(C)C3=CC=C(C4=COC=N4)C=C3)C=CN2C(C)=C1 BGFXQLIFXSVVLS-UHFFFAOYSA-N 0.000 description 2
- YUOXPHLIRXCZFW-UHFFFAOYSA-N COCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(C(F)F)=C1 Chemical compound COCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(C(F)F)=C1 YUOXPHLIRXCZFW-UHFFFAOYSA-N 0.000 description 2
- GALHPEJMWLISRV-UHFFFAOYSA-N COCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(C2CC2)=C1 Chemical compound COCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(C2CC2)=C1 GALHPEJMWLISRV-UHFFFAOYSA-N 0.000 description 2
- GPGROZADICYFSN-IBGZPJMESA-N COCC1=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN2C(C)=C1 Chemical compound COCC1=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN2C(C)=C1 GPGROZADICYFSN-IBGZPJMESA-N 0.000 description 2
- KRIKQEGHDPPYBF-QAQDUYKDSA-N COCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound COCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 KRIKQEGHDPPYBF-QAQDUYKDSA-N 0.000 description 2
- IWVACBOYILKEBY-UHFFFAOYSA-N COCCOC1=CC2=C(C=C1)CCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound COCCOC1=CC2=C(C=C1)CCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 IWVACBOYILKEBY-UHFFFAOYSA-N 0.000 description 2
- NYQZQZOBXKRYOK-UHFFFAOYSA-N COCCOC1=CC2=C(C=C1)OCCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound COCCOC1=CC2=C(C=C1)OCCC2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 NYQZQZOBXKRYOK-UHFFFAOYSA-N 0.000 description 2
- SUHGPKXMZVCYJR-NRFANRHFSA-N COCCOCC1=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN2C(C)=C1 Chemical compound COCCOCC1=NC2=C(C(=O)N[C@H]3CCCC4=C3C=CC=C4)C=CN2C(C)=C1 SUHGPKXMZVCYJR-NRFANRHFSA-N 0.000 description 2
- UWWQVRYHSYVZPW-HDJSIYSDSA-N CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 UWWQVRYHSYVZPW-HDJSIYSDSA-N 0.000 description 2
- MZYCNMMGXLIFOQ-HDJSIYSDSA-N CO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 MZYCNMMGXLIFOQ-HDJSIYSDSA-N 0.000 description 2
- WZZPRSXSDRFOMQ-SFHVURJKSA-N O=C(N[C@H]1CCCC2=C1C=CC=C2)C1=C2N=CC=C(C3CC3)N2C=C1 Chemical compound O=C(N[C@H]1CCCC2=C1C=CC=C2)C1=C2N=CC=C(C3CC3)N2C=C1 WZZPRSXSDRFOMQ-SFHVURJKSA-N 0.000 description 2
- QEIUFKJMPKEAHA-VAAKKRCDSA-N [2H]C1(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CCCC2=C1C=CC=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CCCC2=C1C=CC=C2 QEIUFKJMPKEAHA-VAAKKRCDSA-N 0.000 description 2
- ARVMUUPXDKNPQB-QNLPYAOMSA-N [2H]C1(NC(=O)C2=C3N=C(NC(C)=O)C=C(C)N3C=C2)CCOC2=C1C=CC=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=C(NC(C)=O)C=C(C)N3C=C2)CCOC2=C1C=CC=C2 ARVMUUPXDKNPQB-QNLPYAOMSA-N 0.000 description 2
- YWQQXVFHQYJBDF-OKWSDYJOSA-N [2H]C1(NC(=O)C2=C3N=CC=C(C)N3C=C2)CCCC2=C1C=CC=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=CC=C(C)N3C=C2)CCCC2=C1C=CC=C2 YWQQXVFHQYJBDF-OKWSDYJOSA-N 0.000 description 2
- FMLUTDAFNGHEFE-CXVYKYTNSA-N [2H]C1=CC(C(=O)NC2=CC=C(C3=COC=N3)C=C2)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 Chemical compound [2H]C1=CC(C(=O)NC2=CC=C(C3=COC=N3)C=C2)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 FMLUTDAFNGHEFE-CXVYKYTNSA-N 0.000 description 2
- RDEIIHHSWJUBTE-KBXBZICCSA-N *.B.C.CC.CC.CC.CC.CC(=O)C(C)C(C)=O.CC1=NC2=C(C(=O)O)C=CN2C(C)=C1C.CC1=NC2=C(C(N)=O)C=CN2C(C)=C1C.CCOC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.NC(=O)C1=C(N)NC=C1.[2HH] Chemical compound *.B.C.CC.CC.CC.CC.CC(=O)C(C)C(C)=O.CC1=NC2=C(C(=O)O)C=CN2C(C)=C1C.CC1=NC2=C(C(N)=O)C=CN2C(C)=C1C.CCOC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.NC(=O)C1=C(N)NC=C1.[2HH] RDEIIHHSWJUBTE-KBXBZICCSA-N 0.000 description 1
- WIIWKSGQZDPQLF-UHFFFAOYSA-N C#CC1=CC=C(NC(=O)C2=C3N=C(C)C(OC)=C(C)N3C=C2)C=C1 Chemical compound C#CC1=CC=C(NC(=O)C2=C3N=C(C)C(OC)=C(C)N3C=C2)C=C1 WIIWKSGQZDPQLF-UHFFFAOYSA-N 0.000 description 1
- JUCQLWQPKCHAAI-HXQWUSOTSA-N C.C.CC.CC.CC.CC.CC1=NC2=C(C(=O)O)C=CN2C(C)=C1C.CCN.CCN.CCN.CCNC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.CCNC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.CCOC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.F.[2HH] Chemical compound C.C.CC.CC.CC.CC.CC1=NC2=C(C(=O)O)C=CN2C(C)=C1C.CCN.CCN.CCN.CCNC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.CCNC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.CCOC(=O)C1=C2N=C(C)C(C)=C(C)N2C=C1.F.[2HH] JUCQLWQPKCHAAI-HXQWUSOTSA-N 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N C1Oc2ccccc2O1 Chemical compound C1Oc2ccccc2O1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- UOIYYJFUVUIFKC-UHFFFAOYSA-N CC(C)C1=CC=C2CCCC2=C1.CC(C)C1=CC=C2CCCCC2=C1.CC(C)C1CCC2=C(C=CC=C2)C1 Chemical compound CC(C)C1=CC=C2CCCC2=C1.CC(C)C1=CC=C2CCCCC2=C1.CC(C)C1CCC2=C(C=CC=C2)C1 UOIYYJFUVUIFKC-UHFFFAOYSA-N 0.000 description 1
- SIRIWLZEXJILKI-UHFFFAOYSA-N CC(C)C1=CC=C2OCOC2=C1.CC(C)C1=CN=C2CCCC2=C1.[H]N1C=CC2=CC(C(C)C)=CC=C21.[H]N1N=CC2=CC=C(C(C)C)C=C21 Chemical compound CC(C)C1=CC=C2OCOC2=C1.CC(C)C1=CN=C2CCCC2=C1.[H]N1C=CC2=CC(C(C)C)=CC=C21.[H]N1N=CC2=CC=C(C(C)C)C=C21 SIRIWLZEXJILKI-UHFFFAOYSA-N 0.000 description 1
- QDNJZGPXCQXXQG-UHFFFAOYSA-N CC(C)C1CC(C(C)C)C1 Chemical compound CC(C)C1CC(C(C)C)C1 QDNJZGPXCQXXQG-UHFFFAOYSA-N 0.000 description 1
- CITAJXRBKWJHJR-UHFFFAOYSA-N CC(C)C1CCC(C(C)C)N1 Chemical compound CC(C)C1CCC(C(C)C)N1 CITAJXRBKWJHJR-UHFFFAOYSA-N 0.000 description 1
- SHNGLZSBGSEZFU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC(C)C)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC(C)C)C=CN12 SHNGLZSBGSEZFU-UHFFFAOYSA-N 0.000 description 1
- MSJFOARJBNFVBS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC(C)=NO3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC(C)=NO3)C=CN12 MSJFOARJBNFVBS-UHFFFAOYSA-N 0.000 description 1
- LLPMFGVZYVKBPD-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=NC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CC=NC=C3)C=CN12 LLPMFGVZYVKBPD-UHFFFAOYSA-N 0.000 description 1
- WHXXGVVXNVZMOM-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CN=C(C)O3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=CN=C(C)O3)C=CN12 WHXXGVVXNVZMOM-UHFFFAOYSA-N 0.000 description 1
- NMLFUBDJNNYJFF-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=NC=CO3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=C/C4=C(\C=C/3)CCC4OC3=NC=CO3)C=CN12 NMLFUBDJNNYJFF-UHFFFAOYSA-N 0.000 description 1
- YORJYAYYDSMHOP-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CSC=N4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(C4=CSC=N4)C=C3)C=CN12 YORJYAYYDSMHOP-UHFFFAOYSA-N 0.000 description 1
- IIVKPKINXKOTBR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCCN4CCOCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCCN4CCOCC4)C=C3)C=CN12 IIVKPKINXKOTBR-UHFFFAOYSA-N 0.000 description 1
- WOZVDLQDMOCXJK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN)C=C3)C=CN12 WOZVDLQDMOCXJK-UHFFFAOYSA-N 0.000 description 1
- YAWSJEHHTUIXSM-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCNCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCNCC4)C=C3)C=CN12 YAWSJEHHTUIXSM-UHFFFAOYSA-N 0.000 description 1
- YVEHSSLKWWHUAU-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCOCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCCN4CCOCC4)C=C3)C=CN12 YVEHSSLKWWHUAU-UHFFFAOYSA-N 0.000 description 1
- UAOSKFWYTPFNSH-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCN4CCOCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCCN4CCOCC4)C=C3)C=CN12 UAOSKFWYTPFNSH-UHFFFAOYSA-N 0.000 description 1
- QDSRPNKXAYPAPQ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCN4CCOCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCN4CCOCC4)C=C3)C=CN12 QDSRPNKXAYPAPQ-UHFFFAOYSA-N 0.000 description 1
- ZEWKLQTWWNWQBJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCOCCN4CCOCC4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CC=C(OCCOCCN4CCOCC4)C=C3)C=CN12 ZEWKLQTWWNWQBJ-UHFFFAOYSA-N 0.000 description 1
- BKKMWRUJIUIPHV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CC=CO4)C=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=CN=C(C4=CC=CO4)C=C3)C=CN12 BKKMWRUJIUIPHV-UHFFFAOYSA-N 0.000 description 1
- RJMLAZGMTOGAKV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3=NOC(C4(C(F)(F)F)CC4)=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3=NOC(C4(C(F)(F)F)CC4)=C3)C=CN12 RJMLAZGMTOGAKV-UHFFFAOYSA-N 0.000 description 1
- ZCMUUAGXWSTNBR-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC=C(CCCO)C4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC=C(CCCO)C4=C3C=CC=C4)C=CN12 ZCMUUAGXWSTNBR-UHFFFAOYSA-N 0.000 description 1
- RBAISIHXZAYSHK-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CC=C(CCCO)C4=C3C=CC=C4)C=CN12.CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CC=C(CCCO)C4=C3C=CC=C4)C=CN12.CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C4=C3C=CC=C4)C=CN12 RBAISIHXZAYSHK-UHFFFAOYSA-N 0.000 description 1
- WNFTVHXREYSHJV-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=CC=CO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=CC=CO4)CC3)C=CN12 WNFTVHXREYSHJV-UHFFFAOYSA-N 0.000 description 1
- DCLOFQVBDFGPAS-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=COC=N4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(C4=COC=N4)CC3)C=CN12 DCLOFQVBDFGPAS-UHFFFAOYSA-N 0.000 description 1
- TYACAYYTLAVTRA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CS4)C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CS4)C3)C=CN12 TYACAYYTLAVTRA-UHFFFAOYSA-N 0.000 description 1
- XXZAUBHUTFSBLL-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CS4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=CC=CS4)CC3)C=CN12 XXZAUBHUTFSBLL-UHFFFAOYSA-N 0.000 description 1
- PSSIYPHROYVJKA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=NC=CO4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4=NC=CO4)CC3)C=CN12 PSSIYPHROYVJKA-UHFFFAOYSA-N 0.000 description 1
- ZNALVJBTLWLRAF-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4CCC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC(OC4CCC4)CC3)C=CN12 ZNALVJBTLWLRAF-UHFFFAOYSA-N 0.000 description 1
- YZCUPENMXFLWEA-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4(CCCO4)C4=C3C=CC=C4)C=CN12 YZCUPENMXFLWEA-UHFFFAOYSA-N 0.000 description 1
- QDODMGUAZNSCSC-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C3C=CC=C4)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)NC3CCC4=C3C=CC=C4)C=CN12 QDODMGUAZNSCSC-UHFFFAOYSA-N 0.000 description 1
- NUWQFIPRLJSUTE-CALCHBBNSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OCC(C)(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OCC(C)(C)C)CC3)C=CN12 NUWQFIPRLJSUTE-CALCHBBNSA-N 0.000 description 1
- QAFRKIFCTWPFGK-ZDROTVTNSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OCC(C)(C)C)CC3)C=CN12.CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@@H](OCC(C)(C)C)CC3)C=CN12.CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)C=CN12 QAFRKIFCTWPFGK-ZDROTVTNSA-N 0.000 description 1
- ZNALVJBTLWLRAF-JCNLHEQBSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CCC4)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OC4CCC4)CC3)C=CN12 ZNALVJBTLWLRAF-JCNLHEQBSA-N 0.000 description 1
- NUWQFIPRLJSUTE-QAQDUYKDSA-N CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)C=CN12 NUWQFIPRLJSUTE-QAQDUYKDSA-N 0.000 description 1
- HQQHQJYFJNYCLA-CIEDQVTBSA-N CC1=CC(C)=NC2=C(C(=O)N[C@]34CC[C@H](CC3)C3=C4C=CC=C3)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)N[C@]34CC[C@H](CC3)C3=C4C=CC=C3)C=CN12 HQQHQJYFJNYCLA-CIEDQVTBSA-N 0.000 description 1
- UVVSYZKSGZJKNJ-UHFFFAOYSA-N CC1=CC(C)=NC2=C(C(=O)O)C=CN12 Chemical compound CC1=CC(C)=NC2=C(C(=O)O)C=CN12 UVVSYZKSGZJKNJ-UHFFFAOYSA-N 0.000 description 1
- ZMLKQGKERQERKE-UHFFFAOYSA-N CC1=CC(C2=NC=CO2)=CC(F)=C1NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound CC1=CC(C2=NC=CO2)=CC(F)=C1NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 ZMLKQGKERQERKE-UHFFFAOYSA-N 0.000 description 1
- CXKMIYNDWFITHE-UHFFFAOYSA-N CCCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(COC)=C1 Chemical compound CCCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(COC)=C1 CXKMIYNDWFITHE-UHFFFAOYSA-N 0.000 description 1
- ZAQCIHMBPKNCSU-UHFFFAOYSA-N CCCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(COC)=C1.COCC1=CC(C2CC2)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 Chemical compound CCCC1=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN2C(COC)=C1.COCC1=CC(C2CC2)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 ZAQCIHMBPKNCSU-UHFFFAOYSA-N 0.000 description 1
- UZIKFDNBONYHBS-UHFFFAOYSA-N CCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C(OC)=C(C)N3C=C2)C=C1 Chemical compound CCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C(OC)=C(C)N3C=C2)C=C1 UZIKFDNBONYHBS-UHFFFAOYSA-N 0.000 description 1
- RFENDAJCKWPVFL-UHFFFAOYSA-N CCCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CCCCCOC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 RFENDAJCKWPVFL-UHFFFAOYSA-N 0.000 description 1
- VGJGQKOIDSGKID-XGPVDZAGSA-N CCCCO[C@@H]1C[C@@H]2CC[C@H](C1)[C@@H]2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound CCCCO[C@@H]1C[C@@H]2CC[C@H](C1)[C@@H]2NC(=O)C1=C2N=C(C)C=C(C)N2C=C1 VGJGQKOIDSGKID-XGPVDZAGSA-N 0.000 description 1
- WNEJJYMBIGETDN-UAPYVXQJSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CC1 WNEJJYMBIGETDN-UAPYVXQJSA-N 0.000 description 1
- LMBMOQCELPXEDN-RIWVCEGDSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CC1.CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CC1.CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CC1 LMBMOQCELPXEDN-RIWVCEGDSA-N 0.000 description 1
- BVPPDSFZCTWFJW-UAPYVXQJSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C4CC4)C=C(COC)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C4CC4)C=C(COC)N3C=C2)CC1 BVPPDSFZCTWFJW-UAPYVXQJSA-N 0.000 description 1
- JVMRXKPNCANOLR-GIPQTKILSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C4CC4)C=C(COC)N3C=C2)CC1.CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(CCC)C=C(COC)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(C4CC4)C=C(COC)N3C=C2)CC1.CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(CCC)C=C(COC)N3C=C2)CC1 JVMRXKPNCANOLR-GIPQTKILSA-N 0.000 description 1
- FWUSOZZBLRMNBX-IRJFHVNHSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(CCC)C=C(COC)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(CCC)C=C(COC)N3C=C2)CC1 FWUSOZZBLRMNBX-IRJFHVNHSA-N 0.000 description 1
- ORSLPBNJHQNURH-UAPYVXQJSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CC1 ORSLPBNJHQNURH-UAPYVXQJSA-N 0.000 description 1
- FFKPBTBVXKUYOZ-SHTZXODSSA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 FFKPBTBVXKUYOZ-SHTZXODSSA-N 0.000 description 1
- MFDOFSOIDQFHBU-WKILWMFISA-N CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(NC)C=C(C)N3C=C2)CC1 Chemical compound CCCCO[C@H]1CC[C@H](NC(=O)C2=C3N=C(NC)C=C(C)N3C=C2)CC1 MFDOFSOIDQFHBU-WKILWMFISA-N 0.000 description 1
- HTSUVVSVMUNHTP-UHFFFAOYSA-N CCCOC1CC(CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCOC1CC(CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 HTSUVVSVMUNHTP-UHFFFAOYSA-N 0.000 description 1
- HTSUVVSVMUNHTP-SHTZXODSSA-N CCCO[C@H]1C[C@H](CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 Chemical compound CCCO[C@H]1C[C@H](CNC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C1 HTSUVVSVMUNHTP-SHTZXODSSA-N 0.000 description 1
- RFCBAHLYBGNBFA-UHFFFAOYSA-N CCOC(=O)C1=C2N=C(C)C=C(C)N2C=C1 Chemical compound CCOC(=O)C1=C2N=C(C)C=C(C)N2C=C1 RFCBAHLYBGNBFA-UHFFFAOYSA-N 0.000 description 1
- AHZOYZVFBYYJSB-UHFFFAOYSA-N CNC1=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN2C(C)=C1 Chemical compound CNC1=NC2=C(C(=O)NC3C4=C(C=CC=C4)C4CC3C4)C=CN2C(C)=C1 AHZOYZVFBYYJSB-UHFFFAOYSA-N 0.000 description 1
- HLJSFWLFOQLACD-WKILWMFISA-N CNC1=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN2C(C)=C1 Chemical compound CNC1=NC2=C(C(=O)N[C@H]3CC[C@H](OCC(C)C)CC3)C=CN2C(C)=C1 HLJSFWLFOQLACD-WKILWMFISA-N 0.000 description 1
- FRWLTMOALHBEGO-UHFFFAOYSA-N CNCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 Chemical compound CNCCCCOC1=CC=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C=C1 FRWLTMOALHBEGO-UHFFFAOYSA-N 0.000 description 1
- HTRJWODAVBZJRM-UHFFFAOYSA-N COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C(F)=CC(C2=NC=CO2)=C1 Chemical compound COC1=C(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)C(F)=CC(C2=NC=CO2)=C1 HTRJWODAVBZJRM-UHFFFAOYSA-N 0.000 description 1
- AJOFVBVMFUYZBY-UHFFFAOYSA-N COCC#CC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound COCC#CC1CCC(NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 AJOFVBVMFUYZBY-UHFFFAOYSA-N 0.000 description 1
- JHWFNLQTCIGVTI-UHFFFAOYSA-N COCC1=CC(C(C)C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12 Chemical compound COCC1=CC(C(C)C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12 JHWFNLQTCIGVTI-UHFFFAOYSA-N 0.000 description 1
- RIYXTTUCWAQUQG-UHFFFAOYSA-N COCC1=CC(C(C)C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12.COCC1=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN2C(C(C)C)=C1 Chemical compound COCC1=CC(C(C)C)=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN12.COCC1=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN2C(C(C)C)=C1 RIYXTTUCWAQUQG-UHFFFAOYSA-N 0.000 description 1
- UASROGRUZZTMIK-UHFFFAOYSA-N COCC1=CC(C2CC2)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 Chemical compound COCC1=CC(C2CC2)=NC2=C(C(=O)NC3(C)CCOC4=C3C=C(F)C(F)=C4)C=CN12 UASROGRUZZTMIK-UHFFFAOYSA-N 0.000 description 1
- HDMWVLICTAYUEJ-UHFFFAOYSA-N COCC1=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN2C(C(C)C)=C1 Chemical compound COCC1=NC2=C(C(=O)NC3(C)CCCC4=C3C=NC=N4)C=CN2C(C(C)C)=C1 HDMWVLICTAYUEJ-UHFFFAOYSA-N 0.000 description 1
- MLFPLHCUXYLIDA-IYBDPMFKSA-N CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 MLFPLHCUXYLIDA-IYBDPMFKSA-N 0.000 description 1
- AJKOFQCMCGNFSK-DIPRJGKISA-N CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1.CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1.CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 AJKOFQCMCGNFSK-DIPRJGKISA-N 0.000 description 1
- UWWQVRYHSYVZPW-OKILXGFUSA-N CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 UWWQVRYHSYVZPW-OKILXGFUSA-N 0.000 description 1
- FQGRPCIUBNUKSF-WWDKWCEYSA-N CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1.CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1.CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(Cl)C=C(C)N3C=C2)CC1 FQGRPCIUBNUKSF-WWDKWCEYSA-N 0.000 description 1
- MLFPLHCUXYLIDA-WKILWMFISA-N CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 Chemical compound CO[C@H]1CC[C@H](C(C)(C)NC(=O)C2=C3N=C(C)C=C(C)N3C=C2)CC1 MLFPLHCUXYLIDA-WKILWMFISA-N 0.000 description 1
- VEPPOZWATLJLDT-VAAKKRCDSA-N [2H]C1(NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 VEPPOZWATLJLDT-VAAKKRCDSA-N 0.000 description 1
- UZTQVFRYOAEHHG-JTIZEKHMSA-N [2H]C1(NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CCOC2=C1C=C(F)C(F)=C2.[2H]C1(NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=C(C(C)C)C=C(COC)N3C=C2)CCOC2=C1C=C(F)C(F)=C2.[2H]C1(NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 UZTQVFRYOAEHHG-JTIZEKHMSA-N 0.000 description 1
- DGVJIESDYCDINY-VAAKKRCDSA-N [2H]C1(NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 Chemical compound [2H]C1(NC(=O)C2=C3N=C(COC)C=C(C(C)C)N3C=C2)CCOC2=C1C=C(F)C(F)=C2 DGVJIESDYCDINY-VAAKKRCDSA-N 0.000 description 1
- VGGQSSJOORNYJU-AQYZMPKCSA-N [2H]C1=CC(C(=O)NC(C)(C)C2=CC=C(F)C=C2)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 Chemical compound [2H]C1=CC(C(=O)NC(C)(C)C2=CC=C(F)C=C2)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 VGGQSSJOORNYJU-AQYZMPKCSA-N 0.000 description 1
- VGGQSSJOORNYJU-MIBQVNFTSA-N [2H]C1=CC(C(=O)NC(C)(C)C2=CC=C(F)C=C2)=C2N=C(C)C([2H])=C(C)N12 Chemical compound [2H]C1=CC(C(=O)NC(C)(C)C2=CC=C(F)C=C2)=C2N=C(C)C([2H])=C(C)N12 VGGQSSJOORNYJU-MIBQVNFTSA-N 0.000 description 1
- WLDGUODEFDCGNE-HMQYVOITSA-N [2H]C1=CC(C(=O)NC2(C)CCOC3=C2C=CC=C3)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 Chemical compound [2H]C1=CC(C(=O)NC2(C)CCOC3=C2C=CC=C3)=C2N=C(C)C([2H])=C(C([2H])([2H])[2H])N12 WLDGUODEFDCGNE-HMQYVOITSA-N 0.000 description 1
- WLDGUODEFDCGNE-SQSURYJASA-N [2H]C1=CC(C(=O)NC2(C)CCOC3=C2C=CC=C3)=C2N=C(C)C([2H])=C(C)N12 Chemical compound [2H]C1=CC(C(=O)NC2(C)CCOC3=C2C=CC=C3)=C2N=C(C)C([2H])=C(C)N12 WLDGUODEFDCGNE-SQSURYJASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention provides substituted pyrrolo[1,2-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders in a patient.
- Gaucher disease is a genetic disorder associated with a deficiency of the lysosomal enzyme, glucocerebrosidase. Gaucher disease has been reported to have an incidence of approximately 1 in 20,000 live births in the general population, and it is a common lysosomal storage disorder. Current treatments for patients suffering from this disease include enzyme replacement therapy, which tends to be expensive, analgesics for bone pain relief, and medical procedures such as blood and platelet transfusions, splenectomy, and joint replacement for patients who experience bone erosion. However, new treatment options are needed having improved efficacy across a broader range of patients and/or reduced adverse side effects.
- Parkinson's disease is a degenerative disorder of the central nervous system associated with death of dopamine-containing cells in a region of the midbrain. Parkinson's disease afflicts millions of people, and the incidence of the disease increases with age. Treatment of Parkinson's disease frequently involves use of levodopa and dopamine agonists. However, these drugs can produce significant side effects such as hallucinations, insomnia, nausea, and constipation. Further, patients often develop tolerance to these drugs such that the drugs become ineffective at treating the symptoms of the disease, while sometimes also producing a movement disorder side effect called dyskinesia. Diffuse Lewy Body disease is a dementia that is sometimes confused with Alzheimer's disease.
- the invention provides substituted pyrrolo[1,2-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, in a patient.
- medical disorders e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, in a patient.
- one aspect of the invention provides a family of substituted pyrrolo[1,2-a]pyrimidine and related organic compounds embraced by Formula I that may be used in the methods, compositions, and kits described herein, wherein Formula I is represented by:
- Another aspect of the invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I.
- Another aspect of the invention provides a method of treating a disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, in a patient.
- a disorder e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma
- the method comprises administering to a patient in need thereof a therapeutically effective amount of a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, to treat the disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, or multiple myeloma.
- a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein such as a compound of Formula I
- the disorder e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, or multiple myeloma.
- the invention provides substituted pyrrolo[1,2-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders in a patient.
- the practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, cell biology, and biochemistry. Such techniques are explained in the literature, such as in “Comprehensive Organic Synthesis” (B. M. Trost & I. Fleming, eds., 1991-1992); “Current protocols in molecular biology” (F. M. Ausubel et al., eds., 1987, and periodic updates); and “Current protocols in immunology” (J. E.
- alkyl refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C 1 -C 12 alkyl, C 1 -C 10 alkyl, and C 1 -C 6 alkyl, respectively.
- Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.
- alkylene refers to a diradical of an alkyl group.
- An exemplary alkylene group is —CH 2 CH 2 —.
- haloalkyl refers to an alkyl group that is substituted with at least one halogen.
- halogen for example, —CH 2 F, —CHF 2 , —CF 3 , —CH 2 CF 3 , —CF 2 CF 3 , and the like.
- heteroalkyl refers to an “alkyl” group in which at least one carbon atom has been replaced with a heteroatom (e.g., an O, N, or S atom).
- the heteroalkyl may be, for example, an —O—C 1 -C 10 alkyl group, an —C 1 -C 6 alkylene-O—C 1 -C 6 alkyl group, or a C 1 -C 6 alkylene-OH group.
- the “heteroalkyl” may be 2-8 membered heteroalkyl, indicating that the heteroalkyl contains from 2 to 8 atoms selected from the group consisting of carbon, oxygen, nitrogen, and sulfur.
- the heteroalkyl may be a 2-6 membered, 4-8 membered, or a 5-8 membered heteroalkyl group (which may contain for example 1 or 2 heteroatoms selected from the group oxygen and nitrogen).
- One type of heteroalkyl group is an “alkoxyl” group.
- alkenyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon double bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C 2 -C 12 alkenyl, C 2 -C 10 alkenyl, and C 2 -C 6 alkenyl, respectively.
- alkenyl groups include vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl, and the like.
- alkynyl refers to an unsaturated straight or branched hydrocarbon having at least one carbon-carbon triple bond, such as a straight or branched group of 2-12, 2-10, or 2-6 carbon atoms, referred to herein as C 2 -C 12 alkynyl, C 2 -C 10 alkynyl, and C 2 -C 6 alkynyl, respectively.
- exemplary alkynyl groups include ethynyl, prop-1-yn-1-yl, and but-1-yn-1-yl.
- cycloalkyl refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C 4-8 cycloalkyl,” derived from a cycloalkane.
- exemplary cycloalkyl groups include, but are not limited to, cyclohexanes, cyclopentanes, cyclobutanes and cyclopropanes.
- cycloalkyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl. Cycloalkyl groups can be fused to other cycloalkyl, aryl, or heterocyclyl groups. In certain embodiments, the cycloalkyl group is not substituted, i.
- cycloalkylene refers to a diradical of an cycloalkyl group.
- An exemplary cycloalkylene group is
- partially unsaturated carbocyclyl refers to a monovalent cyclic hydrocarbon that contains at least one double bond between ring atoms where at least one ring of the carbocyclyl is not aromatic.
- the partially unsaturated carbocyclyl may be characterized according to the number of ring carbon atoms.
- the partially unsaturated carbocyclyl may contain 5-14, 5-12, 5-8, or 5-6 ring carbon atoms, and accordingly be referred to as a 5-14, 5-12, 5-8, or 5-6 membered partially unsaturated carbocyclyl, respectively.
- the partially unsaturated carbocyclyl may be in the form of a monocyclic carbocycle, bicyclic carbocycle, tricyclic carbocycle, bridged carbocycle, spirocyclic carbocycle, or other carbocyclic ring system.
- exemplary partially unsaturated carbocyclyl groups include cycloalkenyl groups and bicyclic carbocyclyl groups that are partially unsaturated.
- partially unsaturated carbocyclyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, haloalkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl.
- the partially unsaturated carbocyclyl is not substituted, i.e., it is unsubstituted.
- cycloalkenyl refers to a monovalent unsaturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons containing one carbon-carbon double bond, referred to herein, e.g., as “C 4-8 cycloalkenyl,” derived from a cycloalkane.
- exemplary cycloalkenyl groups include, but are not limited to, cyclohexenes, cyclopentenes, and cyclobutenes.
- cycloalkenyl groups are optionally substituted at one or more ring positions with, for example, alkanoyl, alkoxy, alkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl or thiocarbonyl.
- the cycloalkenyl group is not substituted, i.e., it is unsubstituted.
- aryl is art-recognized and refers to a carbocyclic aromatic group. Representative aryl groups include phenyl, naphthyl, anthracenyl, and the like.
- aryl includes polycyclic ring systems having two or more carbocyclic rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is aromatic and, e.g., the other ring(s) may be cycloalkyls, cycloalkenyls, cycloalkynyls, and/or aryls.
- the aromatic ring may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, —C(O)alkyl, —CO 2 alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl or heteroaryl moieties, —CF 3 , —CN, or the like.
- the aromatic ring is substituted at one or more ring positions with halogen, alkyl, hydroxyl, or alkoxyl. In certain other embodiments, the aromatic ring is not substituted, i.e., it is unsubstituted. In certain embodiments, the aryl group is a 6-10 membered ring structure.
- aralkyl refers to an alkyl group substituted with an aryl group.
- bicyclic carbocyclyl that is partially unsaturated refers to a bicyclic carbocyclic group containing at least one double bond between ring atoms and at least one ring in the bicyclic carbocyclic group is not aromatic.
- Representative examples of a bicyclic carbocyclyl that is partially unsaturated include, for example:
- ortho, meta and para are art-recognized and refer to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively.
- 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
- heterocyclyl and “heterocyclic group” are art-recognized and refer to saturated, partially unsaturated, or aromatic 3- to 10-membered ring structures, alternatively 3- to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
- the number of ring atoms in the heterocyclyl group can be specified using C x -C x nomenclature where x is an integer specifying the number of ring atoms.
- a C 3 -C 7 heterocyclyl group refers to a saturated or partially unsaturated 3- to 7-membered ring structure containing one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
- C 3 -C 7 indicates that the heterocyclic ring contains a total of from 3 to 7 ring atoms, inclusive of any heteroatoms that occupy a ring atom position.
- a C 3 heterocyclyl is aziridinyl.
- Heterocycles may also be mono-, bi-, or other multi-cyclic ring systems including a spirocyclic ring system where at least one ring contains a ring heteroatom.
- a heterocycle may be fused to one or more aryl, partially unsaturated, or saturated rings.
- Heterocyclyl groups include, for example, biotinyl, chromenyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, homopiperidinyl, imidazolidinyl, isoquinolyl, isothiazolidinyl, isooxazolidinyl, morpholinyl, oxolanyl, oxazolidinyl, phenoxanthenyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazolinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidin-2-onyl, pyrrolinyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydropyranyl, tetrahydroquinolyl, thiazolidinyl,
- the heterocyclic ring is optionally substituted at one or more positions with substituents such as alkanoyl, alkoxy, alkyl, alkenyl, alkynyl, amido, amidino, amino, aryl, arylalkyl, azido, carbamate, carbonate, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, imino, ketone, nitro, oxo, phosphate, phosphonato, phosphinato, sulfate, sulfide, sulfonamido, sulfonyl and thiocarbonyl.
- the heterocyclyl group is not substituted, i.e., it is unsubstituted.
- bicyclic heterocyclyl refers to a heterocyclyl group that contains two rings that are fused together.
- Representative examples of a bicyclic heterocyclyl include, for example:
- the bicyclic heterocyclyl is an carbocyclic ring fused to partially unsaturated heterocyclic ring, that together form a bicyclic ring structure having 8-10 ring atoms (e.g., where there are 1, 2, 3, or 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur).
- heterocycloalkyl is art-recognized and refers to a saturated heterocyclyl group as defined above.
- the “heterocycloalkyl” is a 3- to 10-membered ring structures, alternatively a 3- to 7-membered rings, whose ring structures include one to four heteroatoms, such as nitrogen, oxygen, and sulfur.
- heterocycloalkylene refers to a diradical of a heterocycloalkyl group.
- An exemplary heterocycloalkylene group is
- the heterocycloalkylene may contain, for example, 3-6 ring atom (i.e., a 3-6 membered heterocycloalkylene).
- the heterocycloalkylene is a 3-6 membered heterocycloalkylene containing 1, 2, or 3 three heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur.
- heteroaryl is art-recognized and refers to aromatic groups that include at least one ring heteroatom. In certain instances, a heteroaryl group contains 1, 2, 3, or 4 ring heteroatoms. Representative examples of heteroaryl groups include pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl and pyrimidinyl, and the like.
- the heteroaryl ring may be substituted at one or more ring positions with, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, carboxylic acid, —C(O)alkyl, —CO 2 alkyl, carbonyl, carboxyl, alkylthio, sulfonyl, sulfonamido, sulfonamide, ketone, aldehyde, ester, heterocyclyl, aryl or heteroaryl moieties, —CF 3 , —CN, or the like.
- heteroaryl also includes polycyclic ring systems having two or more rings in which two or more carbons are common to two adjoining rings (the rings are “fused rings”) wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, and/or aryls.
- the heteroaryl ring is substituted at one or more ring positions with halogen, alkyl, hydroxyl, or alkoxyl.
- the heteroaryl ring is not substituted, i.e., it is unsubstituted.
- the heteroaryl group is a 5- to 10-membered ring structure, alternatively a 5- to 6-membered ring structure, whose ring structure includes 1, 2, 3, or 4 heteroatoms, such as nitrogen, oxygen, and sulfur.
- heteroarylkyl refers to an alkyl group substituted with a heteroaryl group.
- amine and “amino” are art-recognized and refer to both unsubstituted and substituted amines, e.g., a moiety represented by the general formula —N(R 50 )(R 51 ), wherein R 50 and R 51 each independently represent hydrogen, alkyl, cycloalkyl, heterocyclyl, alkenyl, aryl, aralkyl, or —(CH 2 ) m —R 61 ; or R 50 and R 51 , taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R 61 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.
- R 50 and R 51 each independently represent hydrogen, alkyl, alkenyl, or —(CH 2 ) m —R 61
- alkoxyl or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto.
- Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
- An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(CH 2 ) m —R 61 , where m and R 61 are described above.
- carboxy refers to a radical of the form —R g OC(O)N(R h )—, —R g OC(O)N(R h )R i —, or —OC(O)NR h R i , wherein R g , R h and R i are each independently alkoxy, aryloxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carboxy, cyano, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, nitro, sulfide, sulfonyl, or sulfonamide.
- Exemplary carbamates include arylcarbamates and heteroaryl carbamates, e.g., wherein at least one of R g , R h and R i are independently aryl or heteroaryl, such as phenyl and pyridinyl.
- carbonyl refers to the radical —C(O)—.
- Carboxamido refers to the radical —C(O)NRR′, where R and R′ may be the same or different.
- R and R′ may be independently alkyl, aryl, arylalkyl, cycloalkyl, formyl, haloalkyl, heteroaryl, or heterocyclyl.
- carboxy refers to the radical —COOH or its corresponding salts, e.g. —COONa, etc.
- amide or “amido” as used herein refers to a radical of the form —R a C(O)N(R b )—, —R a C(O)N(R b )R c —, —C(O)NR b R c , or —C(O)NH 2 , wherein R a , R b and R c are each independently alkoxy, alkyl, alkenyl, alkynyl, amide, amino, aryl, arylalkyl, carbamate, cycloalkyl, ester, ether, formyl, halogen, haloalkyl, heteroaryl, heterocyclyl, hydrogen, hydroxyl, ketone, or nitro.
- the amide can be attached to another group through the carbon, the nitrogen, R b , R c , or R a .
- the amide also may be cyclic, for example R b and R c , R a and R b , or R a and R c may be joined to form a 3- to 12-membered ring, such as a 3- to 10-membered ring or a 5- to 6-membered ring.
- amino refers to a radical of the form —C( ⁇ NR)NR′R′′ where R, R′, and R′′ are each independently alkyl, alkenyl, alkynyl, amide, aryl, arylalkyl, cyano, cycloalkyl, haloalkyl, heteroaryl, heterocyclyl, hydroxyl, ketone, or nitro.
- alkanoyl refers to a radical —O—CO-alkyl.
- oxo is art-recognized and refers to a “ ⁇ O” substituent.
- a cyclopentane susbsituted with an oxo group is cyclopentanone.
- sulfonamide or “sulfonamido” as used herein refers to a radical having the structure —N(R r )—S(O) 2 —R s — or —S(O) 2 —N(R r )R s , where R r , and R s can be, for example, hydrogen, alkyl, aryl, cycloalkyl, and heterocyclyl.
- Exemplary sulfonamides include alkylsulfonamides (e.g., where R s is alkyl), arylsulfonamides (e.g., where R s is aryl), cycloalkyl sulfonamides (e.g., where R s is cycloalkyl), and heterocyclyl sulfonamides (e.g., where R s is heterocyclyl), etc.
- sulfonyl refers to a radical having the structure R u SO 2 —, where R u can be alkyl, aryl, cycloalkyl, and heterocyclyl, e.g., alkylsulfonyl.
- alkylsulfonyl refers to an alkyl group attached to a sulfonyl group.
- the compounds of the disclosure may contain one or more chiral centers and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers.
- stereoisomers when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “R” or “S,” depending on the configuration of substituents around the stereogenic carbon atom.
- the present invention encompasses various stereoisomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers.
- Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
- Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Further, enantiomers can be separated using supercritical fluid chromatographic (SFC) techniques described in the literature. Still further, stereoisomers can be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
- SFC supercritical fluid chromatographic
- Geometric isomers can also exist in the compounds of the present invention.
- the symbol denotes a bond that may be a single, double or triple bond as described herein.
- the present invention encompasses the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
- Substituents around a carbon-carbon double bond are designated as being in the “Z” or “E” configuration wherein the terms “Z” and “E” are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the “E” and “Z” isomers.
- Substituents around a carbon-carbon double bond alternatively can be referred to as “cis” or “trans,” where “cis” represents substituents on the same side of the double bond and “trans” represents substituents on opposite sides of the double bond.
- the arrangement of substituents around a carbocyclic ring are designated as “cis” or “trans.”
- the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring.
- Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated “cis/trans.”
- the invention also embraces isotopically labeled compounds of the invention which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- Certain isotopically-labeled disclosed compounds are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labeled compounds of the invention can generally be prepared by following procedures analogous to those disclosed in, e.g., the Examples herein by substituting an isotopically labeled reagent for a non-isotopically labeled reagent.
- the terms “subject” and “patient” refer to organisms to be treated by the methods of the present invention. Such organisms are preferably mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably humans.
- the term “effective amount” refers to the amount of a compound (e.g., a compound of the present invention) sufficient to effect beneficial or desired results.
- An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.
- the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.
- composition refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.
- the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents.
- the compositions also can include stabilizers and preservatives.
- stabilizers and adjuvants see Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. [1975].
- the term “pharmaceutically acceptable salt” refers to any pharmaceutically acceptable salt (e.g., acid or base) of a compound of the present invention which, upon administration to a subject, is capable of providing a compound of this invention or an active metabolite or residue thereof.
- salts of the compounds of the present invention may be derived from inorganic or organic acids and bases.
- acids include, but are not limited to, hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic acid, and the like.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and compounds of formula NW 4 + , wherein W is C 1-4 alkyl, and the like.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- W is C 1-4 alkyl
- salts include, but are not limited to: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate,
- salts of the compounds of the present invention are contemplated as being pharmaceutically acceptable.
- salts of acids and bases that are non-pharmaceutically acceptable may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound.
- HATU O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
- DIPEA diisopropylethylamine
- DCM dimethylformamide
- Boc tert-butoxycarbonyl
- THF trifluoroacetic acid
- NMM N-methylmorpholine
- TAA triethylamine
- Boc anhydride ((Boc) 2 O); dimethylsulfoxide (DMSO); diisopropylethylamine (DIEA); N,N-Dimethylpyridin-4-amine (DMAP); flash column chromatography (FCC); and supercritical fluid chromatography (SFC).
- compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions and kits of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.
- compositions specifying a percentage are by weight unless otherwise specified. Further, if a variable is not accompanied by a definition, then the previous definition of the variable controls.
- substituted pyrrolo[1,2-a]pyrimidine and related organic compounds are contemplated to be useful in the methods, compositions, and kits described herein.
- the substituted pyrrolo[1,2-a]pyrimidine or related organic compound is a compound embraced by Formula I:
- Definitions of the variables in Formula I above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where X 1 is —C(O)N(H)- ⁇ , A 1 is phenyl or 5-6 membered heteroaryl, and Y 1 is 2-8 membered heteroalkyl.
- R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, —(C 1-4 alkylene)-(2-6 membered heteroalkyl), cyclopropyl, halogen, or —N(R 4 ) 2 .
- R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro.
- R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, cyclopropyl, cyano, chloro, or fluoro.
- R 1 is methyl.
- the R 1 groups are located at the 2 and 4 positions of the pyrrolo[1,2-a]pyrimidinyl.
- n is 2. In certain other embodiments, n is 1.
- n is 1. In certain other embodiments, m is 2.
- R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
- R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen.
- X 1 is —C(O)N(H)- ⁇ . In certain embodiments, X 1 is —C(O)N(H)(C 1-6 alkylene)- ⁇ or —C(O)-(3-6 membered heterocycloalkylene containing at least one ring —N(H)— group)- ⁇ .
- a 1 is a cyclic group selected from:
- a 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is phenyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a 5-6 membered heteroaryl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is pyridinyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is C 5-10 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 . In certain embodiments, A 1 is C 3-7 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 . In certain embodiments, A 1 is a cyclopentyl or cyclohexyl, each of which is substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 2 selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, and C 1-6 alkoxyl.
- a 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, or C 1-6 alkoxyl.
- any occurrence of Y 2 is independently C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C 1-3 alkyl. In certain embodiments, Y 2 is cyclopropyl.
- Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 5-6 membered heteroaryl, such as pyrrolyl, furanyl, or pyridinyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl.
- Y 1 is —O—(C 1-7 alkyl). In certain embodiments, Y 1 is —O— butyl, —O-pentyl, or —O-hexyl. In certain embodiments, Y 1 is —(C 1-3 alkylene)-O-(5-6 membered heteroaryl). In certain embodiments, Y 1 is —CH 2 —O-(5-6 membered heteroaryl).
- Y 1 is —CH 2 —O-(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R)
- Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, C 3-7 cycloalkyl, —O-(3-6 membered heterocyclyl), —O-(6-10 membered aryl), or —O—(C 2-6 alkynyl).
- Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
- Y 1 is 5-membered heteroaryl.
- Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-7 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, and C 1-6 alkoxyl.
- Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl. In certain embodiments, Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is C 2-6 alkynyl, —C ⁇ C—(C 1-6 alkylene)-OR 4 , —C ⁇ C—(C 1-6 alkylene)-N(R 3 ) 2 , —(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C 2-6 alkenyl.
- Y 1 is C 2-6 alkynyl.
- Y 1 is —C ⁇ CH.
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-OR 4 .
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-O—(C 1-2 alkyl).
- Y 1 is —C ⁇ C—CH 2 —O—CH 3 .
- the description above describes multiple embodiments relating to compounds of Formula I.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates a compound of Formula I wherein X 1 is —C(O)N(H)- ⁇ , A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-1:
- Definitions of the variables in Formula I-1 above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where X 1 is —C(O)N(H)- ⁇ , A 1 is phenyl or 5-6 membered heteroaryl, and Y 1 is 2-8 membered heteroalkyl.
- R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 represents independently for each occurrence C 1-4 alkyl, C 1-4 haloalkyl, cyclopropyl, cyano, chloro, or fluoro. In certain embodiments, R 1 is methyl. In certain embodiments, the R 1 groups are located at the 2 and 4 positions of the pyrrolo[1,2-a]pyrimidinyl.
- n is 2. In certain other embodiments, n is 1.
- n is 1. In certain other embodiments, m is 2.
- R 2 is hydrogen. In certain embodiments, R 2 is methyl or halogen. In certain embodiments, R 2 is methyl or halomethyl. In certain embodiments, R 2 is methyl or cyclopropyl.
- R 3 and R 4 each represent independently for each occurrence hydrogen, methyl, or ethyl. In certain embodiments, R 3 is hydrogen. In certain embodiments, R 4 is hydrogen.
- X 1 is —C(O)N(H)- ⁇ . In certain embodiments, X 1 is —C(O)N(H)(C 1-6 alkylene)- ⁇ or —C(O)-(3-6 membered heterocycloalkylene containing at least one ring —N(H)— group)- ⁇ .
- a 1 is a cyclic group selected from:
- a 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is phenyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a 5-6 membered heteroaryl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is pyridinyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is C 3-7 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a cyclopentyl or cyclohexyl, each of which is substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 2 selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, and C 1-6 alkoxyl.
- a 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, or C 1-6 alkoxyl.
- any occurrence of Y 2 is independently C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, or hydroxyl. In certain embodiments, any occurrence of Y 2 is independently C 1-3 alkyl. In certain embodiments, Y 2 is cyclopropyl.
- Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl substituted by a 5-6 membered heteroaryl, such as pyrrolyl, furanyl, or pyridinyl. In certain embodiments, Y 1 is a 2-8 membered heteroalkyl.
- Y 1 is —O—(C 1-7 alkyl). In certain embodiments, Y 1 is —O— butyl, —O-pentyl, or —O-hexyl. In certain embodiments, Y 1 is —(C 1-3 alkylene)-O-(5-6 membered heteroaryl). In certain embodiments, Y 1 is —CH 2 —O-(5-6 membered heteroaryl).
- Y 1 is —CH 2 —O-(5-6 membered heteroaryl), wherein the 5-6 membered heteroaryl is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R)
- Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, C 3-7 cycloalkyl, —O-(3-6 membered heterocyclyl), —O-(6-10 membered aryl), or —O—(C 2-6 alkynyl).
- Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
- Y 1 is 5-membered heteroaryl.
- Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-7 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, and C 1-6 alkoxyl.
- Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl. In certain embodiments, Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, thiazolinyl, or triazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is C 2-6 alkynyl, —C ⁇ C—(C 1-6 alkylene)-OR 4 , —C ⁇ C—(C 1-6 alkylene)-N(R 3 ) 2 , —(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C 2-6 alkenyl.
- Y 1 is C 2-6 alkynyl.
- Y 1 is —C ⁇ CH.
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-OR 4 .
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-O—(C 1-2 alkyl).
- Y 1 is —C ⁇ C—CH 2 —O—CH 3 .
- the description above describes multiple embodiments relating to compounds of Formula I-1.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates a compound of Formula I wherein X 1 is —C(O)N(H)- ⁇ , A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-la:
- Definitions of the variables in Formula I-la above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where X 1 is —C(O)N(H)- ⁇ , A 1 is phenyl or 5-6 membered heteroaryl, and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-A:
- Definitions of the variables in Formula I-A above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 , where Y 1 is a 2-8 membered heteroalkyl.
- a 1 is C 3-7 cycloalkyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is phenyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a 5-6 membered heteroaryl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is pyridinyl substituted by Y 1 and 0-1 occurrences of Y 2 .
- any occurrence of Y 2 is independently C 1-3 alkyl, halogen, or C 1-3 haloalkyl.
- Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is —O—(C 1-7 alkyl). In certain embodiments, Y 1 is —O-butyl, —O-pentyl, or —O-hexyl. In certain embodiments, Y 1 is —(C 1-3 alkylene)-O-(5-6 membered heteroaryl). In certain embodiments, Y 1 is —CH 2 —O-(5-6 membered heteroaryl).
- Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, —O-(3-6 membered heterocyclyl), —O-(6-10 membered aryl), or —O—(C 2-6 alkynyl). In certain embodiments, Y 1 is a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
- Y 1 is a 5-membered heteroaryl. In certain embodiments, Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H. In certain embodiments, Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
- Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is C 2-6 alkynyl, —C ⁇ C—(C 1-6 alkylene)-OR 4 , —C ⁇ C—(C 1-6 alkylene)-N(R 3 ) 2 , —(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C 2-6 alkenyl.
- Y 1 is C 2-6 alkynyl.
- Y 1 is —C ⁇ CH.
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-OR 4 .
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-O—(C 1-2 alkyl).
- Y 1 is —C ⁇ C—CH 2 —O—CH 3 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is an 8-12 membered bicyclic carbocyclyl that is partially unsaturated or an 8-12 membered bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0, 1, or 2 occurrences of Y 2 .
- a 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl.
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, or C 1-6 alkoxyl.
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, C 1-6 alkoxyl, or cyano.
- R 1 is methyl. In certain embodiments, R 1 is further selected from halogen and halomethyl, such that R 1 may be methyl, halogen, or halomethyl.
- R 2 is further selected from halogen, such that R 2 may be hydrogen or halogen.
- the description above describes multiple embodiments relating to compounds of Formula I-A.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates a compound of Formula I-A wherein A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-A1:
- Definitions of the variables in Formula I-A1 above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 , where Y 1 is a 2-8 membered heteroalkyl.
- a 1 is phenyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is a 5-6 membered heteroaryl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is pyridinyl substituted by Y 1 and 0-1 occurrences of Y 2 .
- any occurrence of Y 2 is independently C 1-3 alkyl, halogen, or C 1-3 haloalkyl.
- Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is —O—(C 1-7 alkyl). In certain embodiments, Y 1 is —O-butyl, —O-pentyl, or —O-hexyl. In certain embodiments, Y 1 is —(C 1-3 alkylene)-O-(5-6 membered heteroaryl). In certain embodiments, Y 1 is —CH 2 —O-(5-6 membered heteroaryl).
- Y 1 is a 3-10 membered heterocyclyl, 6-10 membered aryl, —O-(3-6 membered heterocyclyl), —O-(6-10 membered aryl), or —O—(C 2-6 alkynyl). In certain embodiments, Y 1 is a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
- Y 1 is a 5-membered heteroaryl. In certain embodiments, Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H. In certain embodiments, Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
- Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- Y 1 is C 2-6 alkynyl, —C ⁇ C—(C 1-6 alkylene)-OR 4 , —C ⁇ C—(C 1-6 alkylene)-N(R 3 ) 2 , —(C 2-4 alkynylene)-(5-6 membered heteroaryl), or C 2-6 alkenyl.
- Y 1 is C 2-6 alkynyl.
- Y 1 is —C ⁇ CH.
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-OR 4 .
- Y 1 is —C ⁇ C—(C 1-6 alkylene)-O—(C 1-2 alkyl).
- Y 1 is —C ⁇ C—CH 2 —O—CH 3 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 .
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0, 1, or 2 occurrences of Y 2 .
- a 1 is a 2-8 membered heteroalkyl optionally substituted by a 6-10 membered aryl or a 3-10 membered heterocyclyl.
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, or C 1-6 alkoxyl.
- a 1 is
- Y 2 represents independently for each occurrence C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, hydroxyl, C 1-6 alkoxyl, or cyano.
- R 1 is methyl. In certain embodiments, R 1 is further selected from halogen and halomethyl, such that R 1 may be methyl, halogen, or halomethyl.
- R 2 is further selected from halogen, such that R 2 may be hydrogen or halogen.
- the description above describes multiple embodiments relating to compounds of Formula I-A.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates a compound of Formula I-A1 wherein A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-B:
- a 1 is a cyclic group selected from phenyl, pyridinyl, cyclopentyl, or cyclohexyl, each of which is substituted by 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 ;
- Y 1 represents, independently for each occurrence, one of the following:
- Y 2 represents, independently for each occurrence, C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, or C 1-6 alkoxyl;
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl.
- Definitions of the variables in Formula I-B above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii), e.g., such as where A 1 is phenyl or pyridinyl, each of which is substituted once by Y 1 , where Y 1 is 2-8 membered heteroalkyl.
- a 1 is phenyl substituted once by Y 1 and 0-1 occurrences of Y 2 .
- a 1 is pyridinyl substituted by Y 1 and 0-1 occurrences of Y 2 .
- any occurrence of Y 2 is independently C 1-3 alkyl, halogen, or C 1-3 haloalkyl.
- Y 1 is a 2-8 membered heteroalkyl optionally substituted by a 6 membered aryl or a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is —O—(C 1-7 alkyl). In certain embodiments, Y 1 is —O-butyl, —O-pentyl, or —O-hexyl. In certain embodiments, Y 1 is —(C 1-3 alkylene)-O-(5-6 membered heteroaryl). In certain embodiments, Y 1 is —CH 2 —O-(5-6 membered heteroaryl).
- Y 1 is a 3-10 membered heterocyclyl, 6 membered aryl, or —O-(3-6 membered heterocyclyl). In certain embodiments, Y 1 is a 3-10 membered heterocyclyl. In certain embodiments, Y 1 is a 3-10 membered heterocyclyl selected from the group consisting of a 5-6 membered heteroaryl and a 5-6 membered heterocycloalkyl.
- Y 1 is a 5-membered heteroaryl. In certain embodiments, Y 1 is a 5-membered heteroaryl substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H. In certain embodiments, Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl.
- Y 1 is furanyl, pyrrolyl, thiophenyl, imidazolyl, pyrazolyl, oxazolyl, or thiazolyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, and C 1-6 alkoxyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl.
- Y 1 is pyridinyl, pyrimidinyl, pyrazinyl, isooxazolyl, isothiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, imidazolinyl, oxazolinyl, pyrazolinyl, or thiazolinyl, each of which is substituted by one or two substituents independently selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, C 1-6 alkoxyl, cyano, —N(R 4 ) 2 , amide, and —CO 2 H.
- the description above describes multiple embodiments relating to compounds of Formula I-B.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates a compound of Formula I-B wherein A 1 is phenyl or pyridinyl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- the compound is a compound of Formula I-C:
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrence of Y 1 and 0, 1, or 2 occurrences of Y 2 ;
- Y 1 represents, independently for each occurrence, one of the following:
- Y 2 represents, independently for each occurrence, C 1-6 alkyl, C 3-6 cycloalkyl, halogen, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, hydroxyl, or C 1-6 alkoxyl;
- R 4 represents independently for each occurrence hydrogen or C 1-4 alkyl.
- Definitions of the variables in Formula I-C above encompass multiple chemical groups.
- the application contemplates embodiments where, for example, i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, ii) the definition is a collection of two or more of the chemical groups selected from those set forth above, and iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).
- a 1 is a bicyclic carbocyclyl that is partially unsaturated or a bicyclic heterocyclyl, each of which is substituted by 0 or 1 occurrences of Y 2 .
- any occurrence of Y 2 is independently C 1-3 alkyl, halogen, or C 1-3 haloalkyl.
- the compound is one of the compounds listed in Table 1 or 2 below or a pharmaceutically acceptable salt thereof.
- the synthetic route illustrated in Scheme 2 depicts an exemplary procedure for preparing substituted pyrrolo[1,2-a]pyrimidine compounds.
- coupling of carboxylic acid D with a variety of substituted aromatic or heteraromatic amines may be accomplished using standard peptide coupling procedures, such as HATU and/or HOBT in DMF in the presence of DIPEA to afford amide E.
- carboxylic ester C may be treated with AlMe 3 to afford the intermediate Weinreb amide, which after reaction with an amine provides substituted amide E.
- the reaction is performed in a stepwise manner where a bromo or iodo-substituted aromatic or heteraromatic amine is coupled with the Weinreb amide to form the iodo or bromo-substituted amide F.
- the bromo or iodo moiety may be used to couple a variety of functional groups using standard coupling procedures, such as acetylenes using Sonogashira coupling, boronic acids using Suzuki coupling, and amines using Buchwald coupling to produce substituted amide E.
- reaction procedures in Scheme 2 are contemplated to be amenable to preparing a wide variety of substituted pyrrolo[1,2-a]pyrimidine carboxamide compounds having different substituents at the A 1 and Y 1 positions.
- a functional group that is part of the A 1 and/or Y 1 would not be amenable to a reaction condition described in Scheme 2, it is contemplated that the functional group can first be protected using standard protecting group chemistry and strategies, and then the protecting group is removed after completing the desired synthetic transformation. See, for example, Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991, for further description of protecting chemistry and strategies.
- a functional group in substituent A 1 and Y 1 can converted to another functional group using standard functional group manipulation procedures known in the art. See, for example, “Comprehensive Organic Synthesis” (B. M. Trost & I. Fleming, eds., 1991-1992).
- the invention provides methods of treating medical disorders, such as Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma, using the substituted pyrrolo[1,2-a]pyrimidine, related compounds, and pharmaceutical compositions described herein.
- Treatment methods include the use of substituted pyrrolo[1,2-a]pyrimidine or related organic compounds described herein as stand-alone therapeutic agents and/or as part of a combination therapy with another therapeutic agent.
- substituted pyrrolo[1,2-a]pyrimidines and related organic compounds described herein may activate glucocerebrosidase (Gcase).
- One aspect of the invention provides a method of treating disorder selected from the group consisting of Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma.
- the method comprises administering to a patient in need thereof a therapeutically effective amount of a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein to treat the disorder.
- the compound may be a compound of Formula I, which, as described above in Section II, is represented by:
- the disorder is Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy. In certain other embodiments, the disorder is Gaucher disease. In certain embodiments, the disorder is Parkinson's disease. In certain embodiments, the disorder is Lewy body disease. In certain embodiments, the disorder is dementia. In certain embodiments, the disorder is a dementia selected from the group consisting of Alzheimer's disease, frontotemporal dementia, and a Lewy body variant of Alzheimer's disease. In certain embodiments, the disorder is multiple system atrophy.
- the disorder is an anxiety disorder, such as panic disorder, social anxiety disorder, or generalized anxiety disorder.
- Efficacy of the compounds in treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, multiple system atrophy, epilepsy, bipolar disorder, schizophrenia, an anxiety disorder, major depression, polycystic kidney disease, type 2 diabetes, open angle glaucoma, multiple sclerosis, and multiple myeloma may be evaluated by testing the compounds in assays known in the art for evaluating efficacy against these diseases and/or, e.g., for activation of glucocerebrosidase (Gcase), as discussed in the Examples below.
- Gcase glucocerebrosidase
- the patient is a human.
- the compound is one of the generic or specific compounds described in Section II, such as a compound of Formula I, a compound embraced by one of the further embodiments describing definitions for certain variables of Formula I, a compound of Formula I-A, or a compound embraced by one of the further embodiments describing definitions for certain variables of Formula I-A.
- the compound is a compound of Formula I-B or I-C or a compound embraced by one of the further embodiments describing definitions for certain variables of Formula I-B or I-C.
- the description above describes multiple embodiments relating to methods of treating various disorders using certain substituted pyrrolo[1,2-a]pyrimidines or related organic compounds.
- the patent application specifically contemplates all combinations of the embodiments.
- the invention contemplates methods for treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy by administering a therapeutically effective amount of a compound of Formula I-A wherein A 1 is phenyl or 5-6 membered heteroaryl, each of which is substituted once by Y 1 and 0, 1, or 2 occurrences of Y 2 , and Y 1 is 2-8 membered heteroalkyl.
- Another aspect of the invention relates to compounds and compositions described herein for use in treating a disorder described herein.
- Another aspect of the invention pertains to use of a compound or composition described herein in the preparation of a medicament for treating a disorder described herein.
- the invention embraces combination therapy, which includes the administration of a substituted pyrrolo[1,2-a]pyrimidine or related compound described herein (such as compound of Formula I, I-A, I-B, or I-C) and a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
- the beneficial effect of the combination may include pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
- Exemplary second agents for use in treating Gaucher disease include, for example, taliglucerase alfa, velaglucerase alfa, eliglustat, and miglustat.
- Exemplary second agents for use in treating Parkinson's disease include, for example, levodopa, pramipexole, ropinirole, rotigotine, and apomorphine.
- the invention provides pharmaceutical compositions comprising a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, I-A, I-B, or I-C.
- the pharmaceutical compositions preferably comprise a therapeutically-effective amount of one or more of the substituted pyrrolo[1,2-a]pyrimidine or related organic compounds described above, formulated together with one or more pharmaceutically acceptable carriers.
- compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., those targeted for buccal, sublingual, and/or systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration by, for example, subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally.
- oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions),
- terapéuticaally-effective amount means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit/risk ratio applicable to any medical treatment.
- phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), le
- Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.
- a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention.
- an aforementioned formulation renders orally bioavailable a compound of the present invention.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxa
- pharmaceutically-acceptable carriers such as sodium citrate or dicalcium phosphate
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be formulated for rapid release, e.g., freeze-dried.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.
- the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.
- the preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.
- parenteral administration and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- the compounds are administered at about 0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100 mg/kg, even more preferably at about 0.5 mg/kg to about 50 mg/kg.
- the effective amount may be less than when the agent is used alone.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.
- kits for treating a disorder comprises: i) instructions for treating a medical disorder, such as Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy; and ii) a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, I-A, I-B, or I-C.
- the kit may comprise one or more unit dosage forms containing an amount of a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I, that is effective for treating said medical disorder, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy.
- the description above describes multiple aspects and embodiments of the invention, including substituted pyrrolo[1,2-a]pyrimidines and related organic compounds, compositions comprising a substituted pyrrolo[1,2-a]pyrimidine or related organic compounds, methods of using the substituted pyrrolo[1,2-a]pyrimidine or related organic compounds, and kits.
- the patent application specifically contemplates all combinations and permutations of the aspects and embodiments.
- the invention contemplates treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy in a human patient by administering a therapeutically effective amount of a compound of Formula I-A.
- the invention contemplates a kit for treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, the kit comprising instructions for treating Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy and ii) a substituted pyrrolo[1,2-a]pyrimidine or related organic compound described herein, such as a compound of Formula I-A.
- reaction mixture was diluted with ethyl acetate (100 mL) and washed with water (75 mL). The aqueous layer was re-extracted with ethyl acetate (3 ⁇ 50 mL). The combined organic layer was washed with water (2 ⁇ 50 mL), followed by brine and dried over Na 2 SO 4 and concentrated in vacuo to obtain crude compound.
- the crude compound was purified by FCC (eluent, 5-25% ethyl acetate in hexane) to afford 4-(3-methoxyprop-1-yn-1-yl)aniline as a light brown solid (230 mg, 62%).
- reaction mixture was quenched with 2N HCl and extracted with ethyl acetate (2 ⁇ 10 mL) to obtain crude compound.
- the crude compound was purified by FCC (eluent, 30-35% ethyl acetate in hexane) to afford the title compound as a light yellow solid (158 mg, 61%).
- reaction mixture was quenched with 2N HCl and extracted with ethyl acetate (2 ⁇ 10 mL) to obtain crude compound.
- the crude compound was purified by FCC (eluent, 30-35% ethyl acetate in hexane) to afford 2,4-dimethyl-N-(6-((trimethylsilyl)ethynyl)pyridin-3-yl)pyrrolo[1,2-a]pyrimidine-8-carboxamide as a yellow solid (105 mg, 31%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/523,775 US20180185368A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462076076P | 2014-11-06 | 2014-11-06 | |
PCT/US2015/059534 WO2016073891A1 (fr) | 2014-11-06 | 2015-11-06 | Pyrrolo[1,2-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux |
US15/523,775 US20180185368A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/059534 A-371-Of-International WO2016073891A1 (fr) | 2014-11-06 | 2015-11-06 | Pyrrolo[1,2-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/453,109 Continuation US10751341B2 (en) | 2014-11-06 | 2019-06-26 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180185368A1 true US20180185368A1 (en) | 2018-07-05 |
Family
ID=55909881
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/523,775 Abandoned US20180185368A1 (en) | 2014-11-06 | 2015-11-06 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US16/453,109 Active US10751341B2 (en) | 2014-11-06 | 2019-06-26 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US16/929,779 Active US11351173B2 (en) | 2014-11-06 | 2020-07-15 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/453,109 Active US10751341B2 (en) | 2014-11-06 | 2019-06-26 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US16/929,779 Active US11351173B2 (en) | 2014-11-06 | 2020-07-15 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
Country Status (5)
Country | Link |
---|---|
US (3) | US20180185368A1 (fr) |
EP (1) | EP3215509B1 (fr) |
AU (2) | AU2015342883B2 (fr) |
CA (1) | CA2966581A1 (fr) |
WO (1) | WO2016073891A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190152980A1 (en) * | 2015-07-01 | 2019-05-23 | Northwestern University | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
US20200071334A1 (en) * | 2018-08-31 | 2020-03-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
US10751341B2 (en) | 2014-11-06 | 2020-08-25 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US10786508B2 (en) | 2014-11-06 | 2020-09-29 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10934298B2 (en) | 2016-04-06 | 2021-03-02 | BIAL—BioTech Investments, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11459325B2 (en) | 2018-01-31 | 2022-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017161137A1 (fr) * | 2016-03-16 | 2017-09-21 | Lysosomal Therapeutics Inc. | Procédé et compositions de traitement d'une maladie neurodégénérative chez un sujet porteur du gène d'une sphingolipidose |
CN110627701B (zh) * | 2019-11-25 | 2020-03-31 | 凯莱英生命科学技术(天津)有限公司 | 一种2-氨基吡咯-3-羧酸乙酯的连续化制备方法 |
JP2023536633A (ja) * | 2020-08-04 | 2023-08-28 | シギロン セラピューティクス, インコーポレイテッド | ヘテロアリール及びヘテロシクリル化合物 |
JP2024518000A (ja) * | 2021-04-30 | 2024-04-23 | ヴァンキア バイオ,インコーポレイテッド | グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
JP3763997B2 (ja) | 1999-05-13 | 2006-04-05 | 富士写真フイルム株式会社 | 感熱記録材料 |
JP4331823B2 (ja) | 1999-05-21 | 2009-09-16 | 富士フイルム株式会社 | ピロロ[1,2−a]−1,3,5−トリアジン−4−オン系化合物 |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
JP4070966B2 (ja) * | 2001-06-28 | 2008-04-02 | 株式会社カネボウ化粧品 | 新規ガラクトシルセラミド類縁体及び用途 |
BR0213026A (pt) | 2001-10-22 | 2004-10-05 | Pfizer | Compostos de imidazopiridina como reguladores do receptor 5-ht4 |
AU2003211424A1 (en) | 2002-03-01 | 2003-09-16 | Yamanouchi Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound |
DOP2003000703A (es) | 2002-09-20 | 2004-03-31 | Pfizer | Compuestos de imidazopiradina como agonistas del receptor 5-ht4 |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
WO2004094418A1 (fr) | 2003-04-21 | 2004-11-04 | Pfizer Inc. | Composes imidazopyridiques ayant une activite agoniste anti-recepteur 5-ht4 et une activite antagoniste anti-recepteur 5-ht3 |
WO2005046612A2 (fr) * | 2003-11-12 | 2005-05-26 | Amicus Therapeutics Inc. | Derives d'hydroxy-piperidine pour traiter la maladie de gaucher |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
CN1922183B (zh) | 2004-02-18 | 2010-05-26 | 万有制药株式会社 | 含氮的稠合杂芳环衍生物 |
CN100528876C (zh) | 2004-06-21 | 2009-08-19 | 弗·哈夫曼-拉罗切有限公司 | 吡唑并嘧啶衍生物 |
WO2006015737A1 (fr) | 2004-08-02 | 2006-02-16 | Schwarz Pharma Ag | Carboxamides d'indolizine et leurs aza- et diaza-derives |
DE102004049363A1 (de) | 2004-10-08 | 2006-04-13 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
JP5094412B2 (ja) | 2005-01-19 | 2012-12-12 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病治療用又は予防用のジペプチジルペプチダーゼ−iv阻害剤としての二環系ピリミジン |
KR100968291B1 (ko) | 2005-02-11 | 2010-07-07 | 에프. 호프만-라 로슈 아게 | Mglur2 길항제로서의 피라졸로-피리미딘 유도체 |
EP1878727A4 (fr) | 2005-04-28 | 2013-11-13 | Kyowa Hakko Kirin Co Ltd | Dérivés de 2-aminoquinazoline |
US7632837B2 (en) | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CN101316847A (zh) | 2005-10-06 | 2008-12-03 | 先灵公司 | 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物 |
US8372851B2 (en) | 2005-10-21 | 2013-02-12 | Exelixis, Inc. | Pyrazolo pyrimidines as casein kinase II (CK2) modulators |
US7795273B2 (en) | 2005-12-08 | 2010-09-14 | Novartis Ag | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
WO2008019363A2 (fr) | 2006-08-07 | 2008-02-14 | Albany Molecular Research, Inc. | 2-alkylbenzoxazole carboxamides en tant que modulateurs de 5ht3 |
WO2008063671A2 (fr) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de métalloprotéase hétérobicycliques |
US20080221083A1 (en) | 2006-11-20 | 2008-09-11 | Matthias Hochgurtel | Heterobicyclic metalloprotease inhibitors |
EP2137187A1 (fr) | 2007-03-28 | 2009-12-30 | Inovacia AB | Pyrazolo [1,5-a]pyrimidines utilisés comme inhibiteurs de la stéaroyl-coa désaturase |
AR067326A1 (es) | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
EP2170842A1 (fr) | 2007-06-21 | 2010-04-07 | Irm, Llc | Inhibiteurs de protéines kinases et leurs procédés d'utilisation |
WO2009060835A1 (fr) | 2007-11-05 | 2009-05-14 | Kyoto University | Nouvelle petite molécule de liaison de l'ubiquitine |
WO2009060197A1 (fr) | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines utilisées comme qu'inhibiteurs de protéine kinases |
WO2009070567A1 (fr) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a] pyrimidines en tant qu'inhibiteurs de protéine kinase |
JP5394404B2 (ja) | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
US20110118236A1 (en) | 2008-03-25 | 2011-05-19 | Michiyo Mochizuki | Heterocyclic compound |
WO2009134973A1 (fr) | 2008-05-01 | 2009-11-05 | Sirtris Pharmaceuticals, Inc. | Quinoléines et analogues apparentés en tant que modulateurs de sirtuine |
UY32174A (es) | 2008-10-14 | 2010-05-31 | Astrazeneca Ab | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones |
EP2348860B1 (fr) | 2008-10-31 | 2015-05-27 | Genentech, Inc. | Composés inhibiteurs de jak à la pyrazolopyrimidine et procédés |
WO2010086040A1 (fr) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines pour traitement de la myopathie de duchenne |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
RU2604062C2 (ru) | 2010-07-13 | 2016-12-10 | Ф.Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА И ТИЕНО[3,2-b]ПИРИМИДИНА В КАЧЕСТВЕ МОДУЛЯТОРОВ IRAK-4 |
WO2012034095A1 (fr) | 2010-09-09 | 2012-03-15 | Irm Llc | Composés et compositions comme inhibiteurs de trk |
TW201217312A (en) | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
WO2012075393A2 (fr) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activateurs de la dégradation protéasomique et leurs utilisations |
US9353117B2 (en) | 2010-12-08 | 2016-05-31 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
EP2688872A4 (fr) | 2011-03-22 | 2014-08-27 | Merck Sharp & Dohme | Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole |
WO2012177997A1 (fr) * | 2011-06-22 | 2012-12-27 | The General Hospital Corporation | Traitement de protéinopathies |
BR112014003496B1 (pt) | 2011-08-18 | 2022-02-22 | Nippon Shinyaku Co., Ltd | Derivado heterocíclico, usos do mesmo e composição farmacêutica |
WO2013030288A1 (fr) | 2011-09-02 | 2013-03-07 | Bayer Intellectual Property Gmbh | Pyrimidines annelées substituées et leur utilisation |
WO2013059119A1 (fr) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Inhibiteurs de la glucosylcéramide synthase et méthodes thérapeutiques à l'aide de ceux-ci |
US9957271B2 (en) | 2011-10-20 | 2018-05-01 | Glaxosmithkline Llc | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013096060A1 (fr) | 2011-12-23 | 2013-06-27 | Novartis Ag | Composés inhibiteurs de l'interaction entre bcl2 et des partenaires de liaison |
US9340549B2 (en) | 2012-03-05 | 2016-05-17 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
MX347917B (es) | 2012-03-09 | 2017-05-17 | Lexicon Pharmaceuticals Inc | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. |
CA2868484A1 (fr) * | 2012-03-28 | 2013-10-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Derives d'acide salicylique utiles a titre d'activateurs de glucocerebrosidase |
KR20150020228A (ko) | 2012-05-31 | 2015-02-25 | 에프. 호프만-라 로슈 아게 | 아미노퀴나졸린 및 피리도피리미딘 유도체 |
CN104395298A (zh) | 2012-06-22 | 2015-03-04 | 住友化学株式会社 | 稠合杂环化合物 |
WO2014025651A1 (fr) | 2012-08-06 | 2014-02-13 | Amgen Inc. | Dérivés de chromane en tant qu'inhibiteurs de trpm8 |
BR112015004858A2 (pt) | 2012-09-05 | 2017-07-04 | Bayer Cropscience Ag | uso de 2-amidobenzimidazóis, 2-amidobenzoxazóis e 2-amidobenzotiazóis substituídos ou sais dos mesmos como substâncias ativas contra estresse abiótico em plantas |
EP2920181B1 (fr) | 2012-11-16 | 2019-01-09 | University Health Network | Composés de pyrazolopyrimidine |
EP2925750A1 (fr) | 2012-11-29 | 2015-10-07 | Karyopharm Therapeutics, Inc. | Composés 2,3-dihydrobenzofuranyle substitués et leurs utilisations |
CN107501275B (zh) | 2012-12-07 | 2019-11-22 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
WO2014141129A2 (fr) | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Nouveaux procédés, composés et compositions pour l'inhibition de ros |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
JPWO2015012328A1 (ja) | 2013-07-24 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
AR097543A1 (es) | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
WO2015073267A1 (fr) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Composés hétéroaryle substitués et méthodes d'utilisation |
ES2895490T3 (es) | 2014-03-27 | 2022-02-21 | Acad Medisch Ct | Iminoazúcares N-(5-(bifen-4-ilmetiloxi)pentil)-sustituidos como inhibidores de glucosilceramida sintasa |
WO2016007736A1 (fr) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines en tant qu'inhibiteurs de lsd1 |
ES2958391T3 (es) | 2014-11-06 | 2024-02-08 | Bial R&D Invest S A | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos |
EP3215509B1 (fr) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidines substituées et leur utilisation dans le traitement de troubles médicaux |
JP6734860B2 (ja) | 2014-11-06 | 2020-08-05 | リソソーマル・セラピューティクス・インコーポレイテッドLysosomal Therapeutics Inc. | 置換ピラゾロ[1,5−a]ピリミジンおよび医療疾患の治療におけるその使用 |
WO2017004405A1 (fr) | 2015-07-01 | 2017-01-05 | Northwestern University | Composés de quinazoline substituée et leurs utilisations pour moduler l'activité de la glucocérébrosidase |
CN108290894A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的4-甲基-吡咯并[1,2-a]嘧啶-8-甲酰胺类化合物及其调节葡糖脑苷脂酶活性的用途 |
WO2017040877A1 (fr) | 2015-09-04 | 2017-03-09 | Lysosomal Therapeutics Inc. | Composés hétérobicycliques de pyrimidinone et leur utilisation dans le traitement de troubles médicaux |
MD3371190T2 (ro) | 2015-11-06 | 2022-09-30 | Incyte Corp | Compuși heterociclici ca inhibitori PI3K-gamma |
WO2017087590A1 (fr) | 2015-11-18 | 2017-05-26 | Bristol-Myers Squibb Company | Composés imidazopyridazine utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifnα |
JP7034935B2 (ja) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | ピロロ[1,2-a]ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
CA3020287A1 (fr) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Composes de pyrazolo[1,5-a]pyrimidinyl carboxamide et leur utilisation dans le traitement de troubles medicaux |
EP3452045A1 (fr) | 2016-05-04 | 2019-03-13 | Lysosomal Therapeutics Inc. | Méthodes de traitement et polythérapies faisant appel à des composés hétérobicycliques activateurs de gcase et autres composés apparentés |
WO2017192931A1 (fr) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | Imidazo[1,2-a]pyridines substituées, imidazo[1,2-a]pyrazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux |
WO2017192930A1 (fr) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | Imidazo[1,2-b]pyridazines substituées, imidazo[1,5-b]pyridazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux |
US20190389865A1 (en) | 2016-05-05 | 2019-12-26 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
EP3728265A1 (fr) | 2017-12-21 | 2020-10-28 | BIAL - BioTech Investments, Inc. | Composé de cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide substitué cristallin et ses utilisations thérapeutiques |
-
2015
- 2015-11-06 EP EP15856385.8A patent/EP3215509B1/fr active Active
- 2015-11-06 CA CA2966581A patent/CA2966581A1/fr not_active Abandoned
- 2015-11-06 US US15/523,775 patent/US20180185368A1/en not_active Abandoned
- 2015-11-06 AU AU2015342883A patent/AU2015342883B2/en not_active Ceased
- 2015-11-06 WO PCT/US2015/059534 patent/WO2016073891A1/fr active Application Filing
-
2019
- 2019-06-26 US US16/453,109 patent/US10751341B2/en active Active
-
2020
- 2020-07-15 US US16/929,779 patent/US11351173B2/en active Active
- 2020-10-02 AU AU2020244605A patent/AU2020244605A1/en not_active Abandoned
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11400095B2 (en) | 2014-11-06 | 2022-08-02 | Bial—R&D Investments, S.A. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US11091492B2 (en) | 2014-11-06 | 2021-08-17 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
US10751341B2 (en) | 2014-11-06 | 2020-08-25 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US10786508B2 (en) | 2014-11-06 | 2020-09-29 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders |
US11351173B2 (en) | 2014-11-06 | 2022-06-07 | Bial—R&D Investments, S.A. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US11932645B2 (en) | 2014-11-06 | 2024-03-19 | Bial—R & D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10442812B2 (en) * | 2015-07-01 | 2019-10-15 | Northwestern University | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
US20190152980A1 (en) * | 2015-07-01 | 2019-05-23 | Northwestern University | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11453675B2 (en) | 2016-04-06 | 2022-09-27 | Bial—R&D Investments, S.A. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US10934298B2 (en) | 2016-04-06 | 2021-03-02 | BIAL—BioTech Investments, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11878979B2 (en) | 2016-05-05 | 2024-01-23 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11459325B2 (en) | 2018-01-31 | 2022-10-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10882865B2 (en) * | 2018-08-31 | 2021-01-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
US20200071334A1 (en) * | 2018-08-31 | 2020-03-05 | Northwestern University | Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity |
Also Published As
Publication number | Publication date |
---|---|
US10751341B2 (en) | 2020-08-25 |
AU2015342883A1 (en) | 2017-06-08 |
EP3215509A1 (fr) | 2017-09-13 |
US20200030331A1 (en) | 2020-01-30 |
AU2020244605A1 (en) | 2020-11-05 |
CA2966581A1 (fr) | 2016-05-12 |
WO2016073891A1 (fr) | 2016-05-12 |
AU2015342883B2 (en) | 2020-07-02 |
US11351173B2 (en) | 2022-06-07 |
EP3215509B1 (fr) | 2020-02-26 |
US20210177853A1 (en) | 2021-06-17 |
EP3215509A4 (fr) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11351173B2 (en) | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | |
US11932645B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders | |
US11400095B2 (en) | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | |
US11124516B2 (en) | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
US11345698B2 (en) | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders | |
US10934298B2 (en) | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | |
US9920061B2 (en) | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders | |
US20190389865A1 (en) | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | |
US20190092789A1 (en) | Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders | |
US20190112316A1 (en) | Thiazolo[3,2-a] pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy | |
TW202319043A (zh) | 3,4-亞甲二氧甲基苯丙胺及相關致幻劑及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: BIAL - BIOTECH INVESTMENTS, INC., PORTUGAL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LYSOSOMAL THERAPEUTICS, INC.;REEL/FRAME:053417/0195 Effective date: 20200717 Owner name: BIAL - BIOTECH INVESTMENTS, INC., PORTUGAL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LYSOSOMAL THERAPEUTICS, INC.;REEL/FRAME:053417/0418 Effective date: 20200717 |